<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>3
<FILENAME>a03-4673_1ex2d1.htm
<DESCRIPTION>EX-2.1
<TEXT>
<html>

<head>



</head>

<body link="blue" vlink="purple">

<div style="font-family:'Times New Roman';">

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 2.1</font></b></p>

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">EXECUTION COPY</font></u></p>

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="border:none;border-top:double windowtext 1.5pt;padding:1.0pt 0in 0in 0in;">

<p align="right" style="border:none;margin:0in 0in .0001pt;padding:0in;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="right" style="border:none;margin:0in 0in .0001pt;padding:0in;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AGREEMENT
AND PLAN OF MERGER</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">by and among</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SICOR INC.,</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SILICON ACQUISITION SUB, INC.</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dated as of October&nbsp;31, 2003</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="border:none;border-bottom:double windowtext 1.5pt;padding:0in 0in 1.0pt 0in;">

<p align="right" style="border:none;margin:0in 0in .0001pt;padding:0in;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TABLE OF CONTENTS</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="13%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:13.8%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Articlei" title="Click to goto ARTICLE&#160;I">ARTICLE&nbsp;I</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#THEMERGER1" title="Click to goto THE MERGER">THE
  MERGER</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TheMerger2" title="Click to goto 1.1">1.1</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TheMerger2" title="Click to goto The Merger">The
  Merger</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#EffectiveTime3" title="Click to goto 1.2">1.2</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#EffectiveTime3" title="Click to goto Effective Time">Effective Time</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="13%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:13.8%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Articleii" title="Click to goto ARTICLE&#160;II">ARTICLE&nbsp;II</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#THESURVIVINGCORPORATION5" title="Click to goto THE SURVIVING CORPORATION">THE SURVIVING CORPORATION</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#EffectoftheMerger6" title="Click to goto 2.1">2.1</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#EffectoftheMerger6" title="Click to goto Effect of the Merger">Effect of the Merger</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CertificateofIncorporation7" title="Click to goto 2.2">2.2</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CertificateofIncorporation7" title="Click to goto Certificate of Incorporation">Certificate of Incorporation</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ByLaws8" title="Click to goto 2.3">2.3</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ByLaws8" title="Click to goto By-Laws">By-Laws</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Directors9" title="Click to goto 2.4">2.4</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Directors9" title="Click to goto Directors">Directors</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Officers10" title="Click to goto 2.5">2.5</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Officers10" title="Click to goto Officers">Officers</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="13%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:13.8%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Articleiii" title="Click to goto ARTICLE&#160;III">ARTICLE&nbsp;III</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#EFFECTOFTHEMERGERONCAPITALSTOCKE12" title="Click to goto EFFECT OF THE MERGER ON CAPITAL STOCK; EXCHANGE OF CERTIFICATES">EFFECT OF THE MERGER ON CAPITAL STOCK;
  EXCHANGE OF CERTIFICATES</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#EffectonCapitalStock13" title="Click to goto 3.1">3.1</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#EffectonCapitalStock13" title="Click to goto Effect on Capital Stock">Effect on Capital Stock</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ExchangeofShareCertificates14" title="Click to goto 3.2">3.2</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ExchangeofShareCertificates14" title="Click to goto Exchange of Share Certificates">Exchange of Share Certificates</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#DissentersRights15" title="Click to goto 3.3">3.3</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#DissentersRights15" title="Click to goto Dissenters&#146; Rights">Dissenters&#146; Rights</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#AdjustmentstoPreventDilution16" title="Click to goto 3.4">3.4</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#AdjustmentstoPreventDilution16" title="Click to goto Adjustments to Prevent Dilution">Adjustments to Prevent Dilution</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Affiliates17" title="Click to goto 3.5">3.5</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Affiliates17" title="Click to goto Affiliates">Affiliates</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#BiomedicalFrontiersWarrants18" title="Click to goto 3.6">3.6</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#BiomedicalFrontiersWarrants18" title="Click to goto Biomedical Frontiers Warrants">Biomedical Frontiers Warrants</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="13%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:13.8%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Articleiv" title="Click to goto ARTICLE&#160;IV">ARTICLE&nbsp;IV</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#THECLOSING20" title="Click to goto THE CLOSING">THE
  CLOSING</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Closing21" title="Click to goto 4.1">4.1</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Closing21" title="Click to goto Closing">Closing</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="13%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:13.8%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Articlev" title="Click to goto ARTICLE&#160;V">ARTICLE&nbsp;V</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#REPRESENTATIONSANDWARRANTIES23" title="Click to goto REPRESENTATIONS AND WARRANTIES">REPRESENTATIONS AND WARRANTIES</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#RepresentationsandWarrantiesofSicor24" title="Click to goto 5.1">5.1</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#RepresentationsandWarrantiesofSicor24" title="Click to goto Representations and Warranties of Sicor">Representations and Warranties of Sicor</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#RepresentationsandWarrantiesofTevaa25" title="Click to goto 5.2">5.2</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#RepresentationsandWarrantiesofTevaa25" title="Click to goto Representations and Warranties of Teva and Merger Sub">Representations and Warranties of Teva and
  Merger Sub</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="13%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:13.8%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Articlevi" title="Click to goto ARTICLE&#160;VI">ARTICLE&nbsp;VI</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CONDUCTOFBUSINESSPENDINGTHEMERGER27" title="Click to goto CONDUCT OF BUSINESS PENDING THE MERGER">CONDUCT OF BUSINESS PENDING THE MERGER</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CovenantsofSicor28" title="Click to goto 6.1">6.1</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CovenantsofSicor28" title="Click to goto Covenants of Sicor">Covenants of Sicor</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CovenantsofTeva29" title="Click to goto 6.2">6.2</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CovenantsofTeva29" title="Click to goto Covenants of Teva">Covenants of Teva</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#NoControlofOtherPartysBusiness30" title="Click to goto 6.3">6.3</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#NoControlofOtherPartysBusiness30" title="Click to goto No Control of Other Party&#146;s Business">No Control of Other Party&#146;s Business</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="13%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:13.8%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Articlevii" title="Click to goto ARTICLE&#160;VII">ARTICLE&nbsp;VII</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ADDITIONALAGREEMENTS32" title="Click to goto ADDITIONAL AGREEMENTS">ADDITIONAL AGREEMENTS</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Access33" title="Click to goto 7.1">7.1</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Access33" title="Click to goto Access">Access</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#AcquisitionProposals34" title="Click to goto 7.2">7.2</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#AcquisitionProposals34" title="Click to goto Acquisition Proposals">Acquisition Proposals</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#SicorStockholdersMeeting35" title="Click to goto 7.3">7.3</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#SicorStockholdersMeeting35" title="Click to goto Sicor Stockholders Meeting">Sicor Stockholders Meeting</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#FilingsOtherActionsNotification36" title="Click to goto 7.4">7.4</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#FilingsOtherActionsNotification36" title="Click to goto Filings; Other Actions; Notification">Filings; Other Actions; Notification</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ProxyStatementProspectusF4Registra37" title="Click to goto 7.5">7.5</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ProxyStatementProspectusF4Registra37" title="Click to goto Proxy Statement/Prospectus; F-4 Registration Statement">Proxy Statement/Prospectus; F-4
  Registration Statement</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#AccountantsComfortLetters38" title="Click to goto 7.6">7.6</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#AccountantsComfortLetters38" title="Click to goto Accountants&#146; Comfort Letters">Accountants&#146; Comfort Letters</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#StockExchangeListing39" title="Click to goto 7.7">7.7</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#StockExchangeListing39" title="Click to goto Stock Exchange Listing">Stock Exchange Listing</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#AffiliateLetters40" title="Click to goto 7.8">7.8</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#AffiliateLetters40" title="Click to goto Affiliate Letters">Affiliate Letters</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ResaleRegistrationStatement41" title="Click to goto 7.9">7.9</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ResaleRegistrationStatement41" title="Click to goto Resale Registration Statement">Resale Registration Statement</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#StockExchangeDelisting42" title="Click to goto 7.10">7.10</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#StockExchangeDelisting42" title="Click to goto Stock Exchange De-listing">Stock Exchange De-listing</a></font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">i</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='i',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Publicity1" title="Click to goto 7.11">7.11</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Publicity1" title="Click to goto Publicity">Publicity</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#BenefitsandOtherEmployeeMatters2" title="Click to goto 7.12">7.12</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#BenefitsandOtherEmployeeMatters2" title="Click to goto Benefits and Other Employee Matters.">Benefits and Other Employee Matters.</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#IndemnificationDirectorsandOfficers3" title="Click to goto 7.13">7.13</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#IndemnificationDirectorsandOfficers3" title="Click to goto Indemnification; Directors&#146; and Officers&#146; Insurance">Indemnification; Directors&#146; and Officers&#146;
  Insurance</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Expenses4" title="Click to goto 7.14">7.14</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Expenses4" title="Click to goto Expenses">Expenses</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TakeoverStatute5" title="Click to goto 7.15">7.15</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TakeoverStatute5" title="Click to goto Takeover Statute">Takeover Statute</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TevaVote6" title="Click to goto 7.16">7.16</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TevaVote6" title="Click to goto Teva Vote">Teva
  Vote</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Section16Matters7" title="Click to goto 7.17">7.17</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Section16Matters7" title="Click to goto Section&#160;16 Matters">Section&nbsp;16 Matters</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CorporateGovernance8" title="Click to goto 7.18">7.18</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CorporateGovernance8" title="Click to goto Corporate Governance.">Corporate Governance.</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="13%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:13.8%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Articleviii" title="Click to goto ARTICLE&#160;VIII">ARTICLE&nbsp;VIII</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CONDITIONS10" title="Click to goto CONDITIONS">CONDITIONS</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ConditionstoEachPartysObligationto11" title="Click to goto 8.1">8.1</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ConditionstoEachPartysObligationto11" title="Click to goto Conditions to Each Party&#146;s Obligation to Effect the Merger">Conditions to Each Party&#146;s Obligation to
  Effect the Merger</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ConditionstoObligationsofTevaandMe12" title="Click to goto 8.2">8.2</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ConditionstoObligationsofTevaandMe12" title="Click to goto Conditions to Obligations of Teva and Merger Sub">Conditions to Obligations of Teva and
  Merger Sub</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ConditionstoObligationofSicor13" title="Click to goto 8.3">8.3</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ConditionstoObligationofSicor13" title="Click to goto Conditions to Obligation of Sicor">Conditions to Obligation of Sicor</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="13%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:13.8%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Articleix" title="Click to goto ARTICLE&#160;IX">ARTICLE&nbsp;IX</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TERMINATION15" title="Click to goto TERMINATION">TERMINATION</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TerminationbyMutualConsent16" title="Click to goto 9.1">9.1</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TerminationbyMutualConsent16" title="Click to goto Termination by Mutual Consent">Termination by Mutual Consent</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TerminationbyEitherTevaorSicor17" title="Click to goto 9.2">9.2</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TerminationbyEitherTevaorSicor17" title="Click to goto Termination by Either Teva or Sicor">Termination by Either Teva or Sicor</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TerminationbySicor18" title="Click to goto 9.3">9.3</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TerminationbySicor18" title="Click to goto Termination by Sicor">Termination by Sicor</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TerminationbyTeva19" title="Click to goto 9.4">9.4</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TerminationbyTeva19" title="Click to goto Termination by Teva">Termination by Teva</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#EffectofTerminationandAbandonment20" title="Click to goto 9.5">9.5</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#EffectofTerminationandAbandonment20" title="Click to goto Effect of Termination and Abandonment">Effect of Termination and Abandonment</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="13%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:13.8%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Articlex" title="Click to goto ARTICLE&#160;X">ARTICLE&nbsp;X</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#MISCELLANEOUSANDGENERAL22" title="Click to goto MISCELLANEOUS AND GENERAL">MISCELLANEOUS AND GENERAL</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Survival23" title="Click to goto 10.1">10.1</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Survival23" title="Click to goto Survival">Survival</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ModificationorAmendment24" title="Click to goto 10.2">10.2</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ModificationorAmendment24" title="Click to goto Modification or Amendment">Modification or Amendment</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#WaiverofConditions25" title="Click to goto 10.3">10.3</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#WaiverofConditions25" title="Click to goto Waiver of Conditions">Waiver of Conditions</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Counterparts26" title="Click to goto 10.4">10.4</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Counterparts26" title="Click to goto Counterparts">Counterparts</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#GOVERNINGLAWANDVENUE27" title="Click to goto 10.5">10.5</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#GOVERNINGLAWANDVENUE27" title="Click to goto GOVERNING LAW AND VENUE">GOVERNING LAW AND VENUE</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Notices28" title="Click to goto 10.6">10.6</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Notices28" title="Click to goto Notices">Notices</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#EntireAgreementNOOTHERREPRESENTATIO29" title="Click to goto 10.7">10.7</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#EntireAgreementNOOTHERREPRESENTATIO29" title="Click to goto Entire Agreement; NO OTHER REPRESENTATIONS">Entire Agreement; NO OTHER REPRESENTATIONS</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#NoThirdPartyBeneficiaries30" title="Click to goto 10.8">10.8</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#NoThirdPartyBeneficiaries30" title="Click to goto No Third-Party Beneficiaries">No Third-Party Beneficiaries</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ObligationsofTevaandofSicor31" title="Click to goto 10.9">10.9</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ObligationsofTevaandofSicor31" title="Click to goto Obligations of Teva and of Sicor">Obligations of Teva and of Sicor</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Severability32" title="Click to goto 10.10">10.10</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Severability32" title="Click to goto Severability">Severability</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Interpretation33" title="Click to goto 10.11">10.11</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Interpretation33" title="Click to goto Interpretation">Interpretation</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Assignment34" title="Click to goto 10.12">10.12</a></font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Assignment34" title="Click to goto Assignment">Assignment</a></font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.14%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="13%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:13.8%;">
  <p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">EXHIBITS</font></u></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="13%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:13.8%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="13%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:13.8%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit A</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form of Sicor Affiliate Letter</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ii</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='ii',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INDEX
OF DEFINED TERMS</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="74%" valign="bottom" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Defined Term</font></b></p>
  </td>
  <td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="center" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>
  </td>
  <td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:12.66%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Section</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:74.68%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Acquisition Proposal</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.2</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agreement</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Forepart</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Affected Employees</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.12(a)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Affiliate Stock.</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.9</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Asbestos</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(m)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Asbestos-Containing Material</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(m)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Audit Date</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(h)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Bankruptcy and Equity Exception</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(c)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Bear Stearns</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(x)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Business Day</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By-Laws</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.3</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash Consideration</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1(c)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Case</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.18(c)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1(c)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate of Incorporation</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.2</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate of Merger</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Closing</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Closing Date</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Code</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1(d)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Compensation and Benefit Plans</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(j)(i)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Confidentiality Agreement</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.7</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Contracts</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(d)(ii)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Conversion Number</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1(c)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Costs</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.13(a)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Depository</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.2(a)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DGCL.</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Recitals</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dissenting Shares</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3(a)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Effective Time</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Employees</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(j)(i)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Environmental Law</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(m)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ERISA</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(j)(i)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ERISA Affiliate</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(j)(iii)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exchange Act</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(a)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exchange Agent</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.2(a)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exchange Fund</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.2(a)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">F-4 Registration Statement</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2(f)(ii)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">FDA</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(k)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Final Order</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1(c)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Foreign Antitrust Filings</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(d)(i)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Governmental Entity</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(d)(i)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Hazardous Substance</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(m)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">HSR Act</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(d)(i)</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">i</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='i',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="74%" valign="bottom" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Defined Term</font></b></p>
  </td>
  <td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="center" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>
  </td>
  <td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:12.66%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Section</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:74.68%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indemnified Parties</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.13(a)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IRS</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(j)(ii)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ISA</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2(d)(i)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">knowledge</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(a)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Laws</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(k)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Liens</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(q)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Merger</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Recitals</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Merger Consideration</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1(c)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Merger Sub</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Forepart</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NASD</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(d)(i)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Nasdaq</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1(d)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Order</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1(d)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pension Plan</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(j)(ii)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Person</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.2(b)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proxy Statement/Prospectus</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(f)(i)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registration Statement.</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2(f)(ii)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registration Statements</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2(f)(ii)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Representatives</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.1</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Resale Registration Statement.</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.9</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Right</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(b)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rights&#133;</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(b)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sarbanes-Oxley Act</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(e)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SEC</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(e)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Securities Act</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(d)(i)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Series I Preferred Stock.</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(b)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Significant Subsidiary</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(a)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sicor</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Forepart</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sicor Balance Sheet</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(g)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sicor Common Stock</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1(b)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sicor Compensation and Benefit Plans</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(j)(i)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sicor Disclosure Schedules</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(a)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sicor Foreign Benefit Plan</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(j)(viii)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sicor Intellectual Property Rights</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(p)(i)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sicor Material Adverse Effect</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(a)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sicor Option</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1(d)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sicor Outstanding Shares.</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.2(a)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sicor Preferred Stock.</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(b)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sicor Reports</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(e)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sicor Required Statutory Approvals</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(d)(i)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sicor Requisite Vote</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(u)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sicor Stock Plans.</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(b)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stockholders Agreement</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Forepart</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stockholders Rights Plan</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(b)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subsidiary</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(a)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Superior Proposal</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.2</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ii</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='ii',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="74%" valign="bottom" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Defined Term</font></b></p>
  </td>
  <td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="center" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>
  </td>
  <td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:12.66%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Section</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:74.68%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Surviving Corporation</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Takeover Statute</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.15</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TASE</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2(d)(i)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tax</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(x)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tax Return</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(x)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Taxable</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(x)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Taxes</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(x)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Termination Date</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.2(a)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Forepart</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva ADRs</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1(c)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva ADSs</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1(c)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva Balance Sheet</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2(g)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva Compensation and Benefit Plans</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2(j)(i)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva&#160; Disclosure Schedules</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(a)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva Foreign Benefit Plan</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2(j)(viii)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva Intellectual Property Rights</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2(o)(i)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva Material Adverse Effect</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2(a)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva Ordinary Shares.</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1(c)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva Reports</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2(e)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva Required Statutory Approvals</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2(d)(i)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva Stock Consideration.</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1(c)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva Stock Plans</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2(b)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">U.S. GAAP</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(a)</font></p>
  </td>
 </tr>
 <tr>
  <td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Voting Debt</font></p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:right;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.66%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1(b)</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">iii</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='iii',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AGREEMENT
AND PLAN OF MERGER</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AGREEMENT AND PLAN OF MERGER (hereinafter called this &#147;<u>Agreement&#148;</u>),
dated as of October&nbsp;31, 2003, by and among SICOR INC., a Delaware
corporation (&#147;<u>Sicor</u>&#148;), TEVA PHARMACEUTICAL INDUSTRIES LIMITED, an
Israeli corporation (&#147;<u>Teva</u>&#148;), and SILICON ACQUISITION SUB, INC., a
Delaware corporation and a wholly owned subsidiary of Teva (&#147;<u>Merger Sub</u>&#148;).</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">W</font></u>&#160; <u>I</u>&#160;
<u>T</u>&#160; <u>N</u>&#160; <u>E</u>&#160;
<u>S</u>&#160; <u>S</u>&#160; <u>E</u>&#160;
<u>T</u>&#160; <u>H</u>:</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, Sicor, Teva and Merger Sub have agreed to enter into a
business combination transaction pursuant to which Merger Sub will merge with
and into Sicor, with Sicor continuing as&#160;
the surviving corporation (the &#147;<u>Merger</u>&#148;), all pursuant to the
terms and conditions set forth in this Agreement and in accordance with the
General Corporation Law of the State of Delaware (the &#147;<u>DGCL</u>&#148;);</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, the respective Boards of Directors of each of Sicor, Teva and
Merger Sub have (i) determined that the Merger and other transactions
contemplated hereby are advisable and are fair to and in the best interests of
Sicor, Teva and Merger Sub and their respective stockholders and (ii) approved
this Agreement and the transactions contemplated hereby;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, as a condition to Teva entering into this Agreement and
incurring the obligations set forth herein, on the date hereof, Teva is
entering into a Stockholders Agreement with certain stockholders of Sicor (the
&#147;<u>Stockholders Agreement</u>&#148;), pursuant to which, among other things, each
of such stockholders has agreed, on the terms and subject to the conditions
thereof, to vote all shares of common stock, par value $0.01 per share, of
Sicor (the &#147;<u>Sicor Common Stock</u>&#148;), owned by each of them to approve this
Agreement and the transactions contemplated hereby; and</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, Sicor, Teva and Merger Sub desire to make certain
representations, warranties, covenants and agreements in connection with the
Merger and to prescribe certain conditions to the Merger;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW, THEREFORE, in consideration of the premises, and of the
representations, warranties, covenants and agreements contained herein, and
intending to be legally bound hereby, the parties hereto agree as follows:</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><a name="Articlei"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;I</font></a></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">THE MERGER</font></u></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="TheMerger2"><u>The Merger</u></a>.&#160;
Upon the terms and subject to the conditions set forth in this
Agreement, and in accordance with the DGCL, at the Effective Time, Merger Sub
shall be merged with and into Sicor and the separate corporate existence of
Merger Sub shall thereupon cease.&#160; Sicor
shall be the surviving corporation in the Merger (sometimes hereinafter
referred to as the &#147;<u>Surviving Corporation</u>&#148;), and shall succeed to and
assume all the rights and obligations of Merger Sub in accordance with
Section&nbsp;259 of the DGCL.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="EffectiveTime3"><u>Effective Time</u></a>.&#160;
As promptly as practicable after the satisfaction or, if permissible,
waiver of the conditions set forth in Article&nbsp;VIII, the parties hereto
shall cause the Merger to be consummated by filing th<u>i</u>s Agreement or a
certificate of merger (the &#147;<u>Certificate of Merger</u>&#148;) with the Secretary
of State of the State of Delaware, in such form as is required by, and executed
in accordance with, the relevant provisions of the DGCL (the date and time of
such filing being the &#147;<u>Effective Time</u>&#148;).&#160; Prior to such filing, a Closing shall be held at the offices of
Pillsbury Winthrop LLP, One Battery Park Plaza, New York, New York 10004, or
such other place as the parties shall agree, for the purpose of confirming the
satisfaction or waiver, as the case may be, of the conditions set forth in
Article&nbsp;VIII.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><a name="Articleii"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;II</font></a></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">THE SURVIVING CORPORATION</font></u></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="EffectoftheMerger6"><u>Effect of the Merger</u></a>.&#160; At the Effective Time, the effect of the
Merger shall be as provided in this Agreement, the Certificate of Merger and
the applicable provisions of the DGCL.&#160;
Without limiting the generality of the foregoing, and subject thereto,
at the Effective Time all the property, rights, privileges, powers and franchises
of Sicor and Merger Sub shall vest in the Surviving Corporation, and all debts,
liabilities and duties of Sicor and Merger Sub shall become the debts,
liabilities and duties of the Surviving Corporation.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="CertificateofIncorporation7"><u>Certificate of Incorporation</u></a>.&#160; At the Effective Time, the certificate of
incorporation of Merger Sub, as in effect immediately prior to the Effective
Time and including the provisions required by Section&nbsp;7.13(d) hereof,
shall be the certificate of incorporation of the Surviving Corporation until
thereafter amended as provided therein or by Law (the &#147;<u>Certificate of
Incorporation</u>&#148;) except that Article&nbsp;I thereof shall be amended, by the
filing of the Certificate of Merger or other appropriate documents, to read in
its entirety as follows: &#147;The name of the corporation is Sicor Inc.&#148;</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="ByLaws8"><u>By-Laws</u></a>.&#160; At the
Effective Time, and without any further action on the part of Sicor or Merger
Sub, the by-laws of Merger Sub, as in effect immediately prior to the Effective
Time, shall be the by-laws of the Surviving Corporation (the &#147;<u>By-Laws</u>&#148;),
until thereafter amended as provided therein, in the Certificate of
Incorporation or in accordance with applicable Law.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="Directors9"><u>Directors</u></a>.&#160;
Subject to requirements of applicable Law, the directors of Merger Sub
immediately prior to the Effective Time shall, from and after the Effective
Time, be the directors of the Surviving Corporation until their successors have
been duly elected or appointed and qualified or until their earlier death,
resignation or removal in accordance with the Certificate of Incorporation and
the By-Laws.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="Officers10"><u>Officers</u></a>.&#160;
Effective as of the Effective Time, Teva shall have caused the
appointment of each of the then executive officers of Sicor to the same
position at the Surviving Corporation, who shall serve until their successors
have been duly elected or appointed and qualified or until their earlier death,
resignation or removal in accordance with the Certificate of Incorporation and
the By-Laws.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='2',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><a name="Articleiii"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;III</font></a></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">EFFECT OF THE MERGER ON CAPITAL STOCK;
EXCHANGE OF CERTIFICATES</font></u></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="EffectonCapitalStock13"><u>Effect on Capital Stock</u></a>.&#160; At the Effective Time, as a result of the
Merger and without any further action on the part of Sicor, Teva, Merger Sub or
any holder of any capital stock of Sicor, Teva or Merger Sub:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Merger
Sub</u>.&#160; Each share of common stock,
par value $.001 per share, of Merger Sub issued and outstanding immediately
prior to the Effective Time shall be converted into one share of common stock,
par value $.001 per share, of the Surviving Corporation, which shall constitute
the only outstanding shares of capital stock of the Surviving Corporation.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Cancellation
of Treasury Stock and Teva-Owned Stock</u>.&#160;
Each share of Sicor Common Stock, and any other shares of capital stock
of Sicor, that is owned by Sicor directly or indirectly or by Teva, Merger Sub
or any other Subsidiary of Teva shall automatically be retired and shall cease
to be outstanding, and no cash or other consideration shall be delivered or
deliverable in exchange therefor.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Conversion
of Sicor Common Stock</u>.&#160; Subject to
Section&nbsp;3.3, each issued and outstanding share of Sicor Common Stock
(other than shares of Sicor Common Stock to be retired in accordance with
Section&nbsp;3.1(b)), including each Right attached thereto, whether or not
then vested or subject to a repurchase option in favor of Sicor, shall be
converted into the right to receive (i) 0.1906 (as may be adjusted pursuant to
Section&nbsp;3.4, the &#147;<u>Conversion Number</u>&#148;) ordinary shares, par value
NIS 0.10 each, of Teva, duly issued and credited as fully paid (the &#147;<u>Teva
Ordinary Shares</u>&#148;) which will trade in the United States in the form of
American Depositary Shares (&#147;<u>Teva ADSs</u>&#148;), evidenced by American
Depositary Receipts (&#147;<u>Teva ADRs</u>&#148;) (together with cash in lieu of
fractional shares as specified in Section&nbsp;3.2, the &#147;<u>Teva Stock
Consideration</u>&#148;), and (ii) $16.50 in cash, without interest (the &#147;<u>Cash
Consideration</u>,&#148; and together with the Teva Stock Consideration, the &#147;<u>Merger
Consideration</u>&#148;).&#160; Each Teva ADS
represents one Teva Ordinary Share.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of the Effective Time, all such shares of Sicor Common Stock shall
no longer be outstanding and shall automatically be retired and shall cease to
be outstanding, and each holder of a certificate representing any such shares
of Sicor Common Stock (a &#147;<u>Certificate</u>&#148;) shall cease to have any rights
with respect thereto, except the right to receive upon the surrender of such
certificates (for each share of Sicor Common Stock previously represented
thereby) the Merger Consideration.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Stock
Options</u>.&#160; As of the Effective Time,
each outstanding option to purchase shares of Sicor Common Stock under the
Sicor Stock Plans (a &#147;<u>Sicor Option</u>&#148;), whether or not exercisable or
vested, shall be assumed by Teva and shall automatically be converted into an
option to purchase Teva Ordinary Shares in the form of Teva ADSs, to be
evidenced by Teva ADRs upon exercise, in an amount and at an exercise price as
determined in accordance with this Section&nbsp;3.1(d).&#160; Teva shall assume each Sicor Stock Plan to
the extent necessary to assume the Sicor Options and, in the event Teva does
not have sufficient registered Teva ADRs to cover the</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='3',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">assumed Sicor Options, Teva
shall, as promptly as practicable after the execution and delivery of this
Agreement, prepare and file with the SEC a Registration Statement with respect
to the Teva ADSs issuable upon the exercise thereof and shall use its best
efforts to cause the Registration Statement to become effective under the
Securities Act as soon as practicable after the date of such filing (and in any
event prior to the Effective Time) and to comply with state securities law and
&#147;blue sky&#148; laws with respect thereto.&#160;
Each Sicor Option so assumed will be subject to, and exercisable and
vested on, the same terms and conditions as under such Sicor Option as of the
Effective Time, except that each assumed Sicor Option shall constitute an
option to acquire that number of Teva ADSs (rounded down to the nearest number
of whole Teva ADSs on a holder-by-holder basis) equal to (a) the number of Teva
ADSs that the holder of such Sicor Option would have been entitled to receive
pursuant to the Merger had such holder exercised such Sicor Option in full
immediately prior to the Effective Time <i><font style="font-style:italic;">plus </font></i>(b) a number of Teva ADSs determined
by dividing (i) the amount of Cash Consideration that the holder of such Sicor
Option would have been entitled to receive pursuant to the Merger had such
holder exercised such Sicor Option in full immediately prior to the Effective
Time <i><font style="font-style:italic;">by </font></i>(ii)
the<b><font style="font-weight:bold;">  </font></b>closing
price per ADS of Teva ADSs on the Business Day immediately prior to the
Effective Time as reported by The Nasdaq Stock Market, Inc. (&#147;<u>Nasdaq</u>&#148;)
National Market System on the Business Day immediately prior to the Effective
Time, at an exercise price per Teva ADS (rounded up to the nearest whole penny)
equal to (x) the aggregate exercise price for the shares of Sicor Common Stock
which otherwise could have been purchased pursuant to such Sicor Option
immediately prior to the Effective Time <i><font style="font-style:italic;">divided by </font></i>(y) the aggregate number of
Teva ADSs deemed to be purchasable (the sum of the amount in clauses (a) and
(b) above) pursuant to such assumed Sicor Option pursuant to and in accordance
with this Section&nbsp;3.1(d).&#160; The
conversion of the Sicor Options provided for in this Section&nbsp;3.1(d) with
respect to any options which are intended to be &#147;incentive stock options&#148; (as
such term is defined in Section&nbsp;422 of the Internal Revenue Code of 1986,
as amended (the &#147;<u>Code</u>&#148;)) shall be effected in a manner consistent with
Section&nbsp;424(a) of the Code.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="ExchangeofShareCertificates14"><u>Exchange of Share Certificates</u></a>.&#160; (a)&#160; <u>Exchange
Agent</u>.&#160; Prior to the Effective Time,
Teva shall designate The Bank of New York, which currently acts as the
depository for the ADSs, or another U.S. bank or trust company reasonably
acceptable to Sicor (in such capacity, the &#147;<u>Depository</u>&#148;), to act as
agent (the &#147;<u>Exchange Agent</u>&#148;) for the holders of shares of Sicor Common
Stock and Sicor Options in connection with the Merger and the payment of the
Merger Consideration or other payment to which holders of shares of Sicor
Common Stock and Sicor Options shall become entitled pursuant to
Section&nbsp;3.1.&#160; Prior to the filing
of the Certificate of Merger with the Secretary of State of the State of
Delaware, Teva or Merger Sub shall deposit with the Exchange Agent (i) cash in
an aggregate amount equal to the product of (A) the number of shares of Sicor
Common Stock issued and outstanding (and not to be retired pursuant to
Section&nbsp;3.1(b)) immediately prior to the Effective Time (the &#147;<u>Sicor Outstanding
Shares</u>&#148;) <i><font style="font-style:italic;">multiplied by</font></i> (B) the Cash Consideration, (ii)<b><font style="font-weight:bold;">  </font></b>certificates
evidencing a sufficient number of Teva Ordinary Shares as would permit the
Exchange Agent to issue Teva ADRs evidencing the number of Teva ADSs equal to
the product of (A) the Sicor Outstanding Shares <i><font style="font-style:italic;">multiplied</font></i> by (B) the Teva
Stock Consideration and (iii) such additional number of Teva ADRs evidencing
Teva ADSs as are required to pay to the holders of Sicor Options the amounts
contemplated by Section&nbsp;3.1(d).&#160;
The deposit made by Teva or Merger Sub, as the case may be, pursuant to
this Section&nbsp;3.2(a) is hereinafter referred to as the &#147;<u>Exchange Fund.</u>&#148;&#160; The Exchange Agent shall</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='4',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">cause the Exchange Fund to be
(i) held for the benefit of the holders of Sicor Common Stock and Sicor Options
and (ii) applied promptly to making the payments provided for in
Section&nbsp;3.1.&#160; The Exchange Fund
shall not be used for any purpose that is not expressly provided for in this
Agreement; provided, that Teva may direct the Exchange Agent invest the
Exchange Fund in obligations of or guaranteed by the United States of America
and backed by the full faith and credit of the United States of America or in
commercial paper obligations rated A-1 or P-1 or better by Moody&#146;s Investors
Services, Inc. or Standard &amp; Poor&#146;s Corporation, respectively. <b><font style="font-weight:bold;">&#160;</font></b>Any interest or other income
resulting from such investments shall be promptly paid to Teva.&#160; Teva shall, prior to the Effective Time,
allot Teva Ordinary Shares referred to in Sections 3.1(c) and 3.1(d) as
designated by Sicor subject to the terms and conditions of this Agreement.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Exchange
Procedures</u>.&#160; As soon as reasonably
practicable after the Effective Time, but in no event later than one (1)
Business Day after the Effective Time, the Surviving Corporation shall cause
the Exchange Agent to mail to each holder of record of shares of Sicor Common
Stock at the Effective Time (i) a letter of transmittal specifying that
delivery of the Certificates shall be effected, and risk of loss and title to
the Certificates shall pass, only upon delivery of the Certificates (or
affidavits of loss in lieu thereof) to the Exchange Agent, such letter of
transmittal to be in such form and have such other provisions as Teva and Sicor
may reasonably agree and (ii) instructions for use in effecting the surrender
of the Certificates in exchange for the Merger Consideration (such instructions
shall include instructions for the payment of the Merger Consideration to a
Person other than the Person in whose name the surrendered Certificate is
registered on the transfer books of Sicor, subject to the receipt of
appropriate documentation for such transfer).&#160;
Upon surrender to the Exchange Agent of a Certificate (or evidence of
loss in lieu thereof) for cancellation together with such letter of
transmittal, duly executed in accordance with the provisions of this
Section&nbsp;3.2(b), the holder of such Certificate shall be entitled to
receive in exchange therefor the Merger Consideration that such holder is
entitled to receive pursuant to this Article&nbsp;III, and the Certificate so
surrendered shall forthwith be cancelled.&#160;
No interest will be paid or accrued on any amount payable upon due
surrender of the Certificates.&#160; In the
event of a transfer of ownership of shares of Sicor Common Stock that is not
registered in the transfer records of Sicor, payment may be issued to such a
transferee if the Certificate formerly representing such shares of Sicor Common
Stock is presented to the Exchange Agent, accompanied by all documents required
to evidence and effect such transfer, and the Person requesting such issuance
pays any transfer or other taxes required by reason of such payment to a Person
other than the registered holder of such Certificate or establishes to the
satisfaction of Teva and Sicor that such tax has been paid or is not
applicable.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No dividends or other distributions with respect to securities of Teva
constituting part of the Merger Consideration shall be paid to the holder of
any Certificates not surrendered until such Certificates are surrendered as
provided in this Section&nbsp;3.2.&#160;
Following such surrender, in addition to the Merger Consideration, there
shall be paid, without interest, to the Person in whose name the securities of
Teva have been registered, (i) at the time of surrender, the amount of all
dividends or other distributions with a record date after the Effective Time
previously paid or payable on the date of such surrender with respect to such
securities and (ii) at the appropriate payment date, the amount of dividends or
other distributions with a record date after the Effective Time and prior to
surrender and with a payment date subsequent to surrender payable with respect
to such securities.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='5',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For the purposes of this Agreement, the term &#147;<u>Person</u>&#148; shall mean
any individual, corporation (including not-for-profit corporations), general or
limited partnership, limited liability company, joint venture, estate, trust,
association, organization, Governmental Entity or other entity of any kind or
nature.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Transfers</u>.&#160; After the Effective Time, there shall be no
registration of transfers on the stock transfer books of Sicor of shares of
Sicor Common Stock that were outstanding immediately prior to the Effective
Time.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination
of Exchange Fund</u>.&#160; Any portion of
the Exchange Fund relating to the Merger Consideration that remains unclaimed
by the stockholders of Sicor or holders of Sicor Options one (1) year after the
Effective Time shall be returned to Teva, the Surviving Corporation or another
Subsidiary of Teva, as may be designated by Teva or the Surviving
Corporation.&#160; Any stockholders of Sicor
or holder of Sicor Options who have not theretofore complied with this
Article&nbsp;III shall thereafter look only to Teva for payment of the Merger
Consideration upon due surrender of their Certificates (or affidavits of loss
in lieu thereof), without any interest thereon.&#160; Notwithstanding the foregoing, none of Teva, the Surviving
Corporation, the Exchange Agent or any other Person shall be liable to any
former holder of shares of Sicor Common Stock or holder of Sicor Options for
any amount properly delivered to a public official pursuant to applicable
abandoned property, escheat or similar Laws.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Lost,
Stolen or Destroyed Certificates</u>.&#160;
In the event that any Certificate shall have been lost, stolen or
destroyed, upon the making of an affidavit of that fact by the Person claiming
such Certificate to be lost, stolen or destroyed and, if required by Teva, the
posting by such Person of a bond in customary amount as indemnity against any
claim that may be made against it or the Surviving Corporation with respect to
such Certificate, the Exchange Agent will issue in exchange for such lost,
stolen or destroyed Certificate the Merger Consideration upon due surrender of
the shares of Sicor Common Stock represented by such Certificate pursuant to
this Agreement.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Fractional
Shares</u>.&#160; Notwithstanding any other
provision of this Agreement to the contrary, no fractional Teva ADSs will be
issued and any holder of shares of Sicor Common Stock entitled to receive a
fractional Teva ADS but for this Section&nbsp;3.2(f) shall be entitled to
receive a cash payment in lieu thereof, which payment shall represent such
holder&#146;s proportionate interest in the net proceeds for the sale by the
Exchange Agent on behalf of such holder of the aggregate fractional Teva ADS
that such holder otherwise would be entitled to receive.&#160; Any such sale shall be made by the Exchange
Agent within five (5) Business Days after the date upon which the Certificate
(or affidavit(s) of loss in lieu thereof) that would otherwise result in the
issuance of such fractional Teva ADSs has been received by the Exchange Agent.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Withholding
Rights</u>.&#160; Each of Teva and the
Surviving Corporation shall be entitled to deduct and withhold from the
consideration otherwise payable to any Person pursuant to this Article&nbsp;III
such amounts as it is required to deduct and withhold with respect to the
making of such payment under provision of any federal, state, local or foreign
tax law.&#160; If Teva or the Surviving
Corporation, as the case may be, so withholds amounts, such amounts shall be
treated for all purposes of this Agreement as having been paid to the holder of
the shares of Sicor</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='6',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common Stock in respect of
which Teva or the Surviving Corporation, as the case may be, made such
deduction and withholding.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="DissentersRights15"><u>Dissenters&#146; Rights</u></a>.&#160; (a)&#160;
Notwithstanding anything in this Agreement to the contrary, shares of
Sicor Common Stock outstanding immediately prior to the Effective Time and held
by a holder who has not voted in favor of the Merger or consented thereto in
writing and who has demanded appraisal for such shares in accordance with
Section&nbsp;262 of the DGCL (the &#147;<u>Dissenting Shares</u>&#148;), shall not be
converted into, or represent the right to receive, the Merger
Consideration.&#160; Such stockholders shall
be entitled to receive, subject to and net of any applicable withholding of Taxes,
payment of the appraised value of such Dissenting Shares held by them in
accordance with the provisions of Section&nbsp;262 of the DGCL, except that all
Dissenting Shares held by stockholders who shall have failed to perfect or who
shall have effectively withdrawn or lost their rights to appraisal of such
Dissenting Shares under Section&nbsp;262 of the DGCL shall thereupon be deemed
to have been converted into, and to have become exchangeable for, as of the
Effective Time, the right to receive the Merger Consideration, without any
interest thereon, upon surrender, in the manner provided in Section&nbsp;3.2,
of the Certificate or Certificates that formerly evidenced such Dissenting
Shares.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sicor
shall give Teva (i) prompt notice of any demands for appraisal received by
Sicor, withdrawals of such demands, and any other instruments served on or
otherwise received by Sicor pursuant to the DGCL and (ii) the right to direct
all negotiations and proceedings with respect to demands for appraisal under
DGCL.&#160; Sicor shall not, except with the
prior written consent of Teva, (x) make any payment with respect to any demands
for appraisal, (y) offer to settle or settle any such demands or (z) waive any
failure to deliver a written demand for appraisal or other action required to
perfect appraisal rights in accordance with the DGCL.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="AdjustmentstoPreventDilution16"><u>Adjustments to Prevent Dilution</u></a>.&#160; In the event that Sicor changes the number
of shares of Sicor Common Stock or securities convertible or exchangeable into
or exercisable for shares of Sicor Common Stock issued and outstanding prior to
the Effective Time as a result of a reclassification, stock split (including a
reverse stock split), stock dividend or distribution, recapitalization, merger,
subdivision, issuer tender or exchange offer, or other similar transaction, the
Merger Consideration shall be equitably adjusted to reflect such change.&#160; If between the date of this Agreement and
the Effective Time, the outstanding Teva Ordinary Shares shall be changed into
a different number of shares by reason of stock dividend, subdivision,
reclassification, split-up, combination or the like, the Conversion Number
shall be appropriately adjusted.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="Affiliates17"><u>Affiliates</u></a>.&#160;
Notwithstanding anything in this Agreement to the contrary, no Teva
Stock Consideration shall be delivered to any Person who is an Affiliate of
Sicor under Rule 145 of the Securities Act until such Person has executed and
delivered to Teva a written agreement substantially in the form of <u>Exhibit A</u>
hereto.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.6</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="BiomedicalFrontiersWarrants18"><u>Biomedical Frontiers Warrants</u></a>.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>At
or following the Effective Time, Biomedical Frontiers Incorporated, its
successor or assigns, shall have the right to purchase and receive upon the
basis and upon the</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='7',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">terms and conditions specified
in the Milestone 1 Warrant Agreement, dated as of July&nbsp;1, 2003, between
Sicor and Biomedical Frontiers Incorporated, including payment of the exercise
price, and in lieu of each share of Sicor Common Stock immediately theretofore
purchasable and receivable upon the exercise of the Milestone 1 Warrants (as
defined in the License, Development and Marketing Agreement, dated as of
September&nbsp;17, 2001, by and between Biomedical Frontiers Incorporated and
Sicor (the &#147;<u>License Agreement</u>&#148;)), the Merger Consideration, without
interest.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In
addition, Sicor or the Surviving Corporation, as applicable, shall issue the
Milestone 4 Warrants (as defined in the License Agreement) when and as required
pursuant to the License Agreement, and such Milestone 4 Warrants shall contain such
terms and conditions, including payment of the exercise price, pursuant to the
License Agreement; provided, that the holder of such Milestone 4 Warrants shall
have the right to purchase and receive upon the basis and upon the terms and
conditions to be specified in the Milestone 4 Warrant Agreement, in lieu of
each share of Sicor Common Stock theretofore purchasable and receivable upon
the exercise of the Milestone 4 Warrants, the Merger Consideration, without
interest.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><a name="Articleiv"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;IV</font></a></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">THE CLOSING</font></u></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="Closing21"><u>Closing</u></a>.&#160; The
closing of the Merger (the &#147;<u>Closing</u>&#148;) shall take place (i) at the
offices of Pillsbury Winthrop LLP, One Battery Park Plaza, New York, New
York&#160; 10004 at 10:00 a.m. Eastern time
on the Business Day after the last to be satisfied or waived of the conditions
set forth in Article&nbsp;VIII (other than those conditions that by their
nature are to be satisfied at the Closing, but subject to the satisfaction or
waiver of those conditions) shall be satisfied or waived (by the party entitled
to the benefit of such condition) in accordance with this Agreement or (ii) at
such other place and time and/or on such other date as Sicor and Teva may agree
in writing (the &#147;<u>Closing Date</u>&#148;).&#160;
For purposes of this Agreement, the term &#147;<u>Business Day</u>&#148; means a
day on which banks are not required or authorized by Law to close in Tel Aviv
or New York City.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><a name="Articlev"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;V</font></a></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">REPRESENTATIONS AND WARRANTIES</font></u></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="RepresentationsandWarrantiesofSicor24"><u>Representations and Warranties of
Sicor</u></a>.&#160; Sicor hereby represents
and warrants to Teva and Merger Sub that:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Organization,
Good Standing and Qualification</u>.&#160;
Each of Sicor and its Significant Subsidiaries is a corporation duly
organized, validly existing and in good standing under the Laws of its
respective jurisdiction of organization and has all requisite corporate or
similar power and authority to own and operate its properties and assets and to
carry on its business as currently conducted in all material respects and is
qualified to do business and is in good standing as a foreign corporation in
each jurisdiction where the ownership or operation of its properties and assets
or conduct of its business requires such qualification, except where the
failure to be so</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='8',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">qualified as a foreign
corporation or be in good standing would not be reasonably likely to have,
either individually or in the aggregate, a Sicor Material Adverse Effect.&#160; Sicor has heretofore made available to Teva
complete and correct copies of Sicor&#146;s and each of its Significant
Subsidiaries&#146; certificate of incorporation and by-laws (or comparable governing
instruments), as amended through the date hereof.&#160; The certificate of incorporation and by-laws (or comparable
governing instruments) of each of Sicor and its Significant Subsidiaries so
made available are in full force and effect.&#160;
Section&nbsp;5.1(a) of the disclosure schedules delivered to Teva by
Sicor on or prior to the date of this Agreement (the &#147;<u>Sicor Disclosure
Schedules</u>&#148;) sets forth a list, as of the date hereof, of all of the
Significant Subsidiaries of Sicor, the jurisdictions under which such
Significant Subsidiaries are incorporated, and the percent of the equity
interest therein owned by Sicor and each Subsidiary of Sicor, as
applicable.&#160; Sicor does not have any Subsidiary
that is organized in Israel.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As used in this Agreement, the term &#147;<u>Subsidiary</u>&#148; means, with
respect to Sicor, Teva or Merger Sub, as the case may be, any entity, whether
incorporated or unincorporated, of which at least a majority of the securities
or ownership interests having by their terms ordinary voting power to elect a
majority of the board of directors or other Persons performing similar
functions is directly or indirectly owned or controlled by such party or by one
or more of its respective Subsidiaries or by such party and any one or more of
its respective Subsidiaries.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As used in this Agreement, the term &#147;<u>Significant Subsidiary</u>&#148;
means a &#147;significant subsidiary&#148; within the meaning of Rule 1.02(w) of
Regulation S-X promulgated pursuant to the Securities Exchange Act of 1934, as
amended (&#147;<u>Exchange Act</u>&#148;).</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As used in this Agreement, the term &#147;<u>Sicor Material Adverse Effect</u>&#148;
means a material adverse effect on the financial condition, business, assets or
results of operations of Sicor and its Subsidiaries taken as a whole; <i><font style="font-style:italic;">provided, however</font></i>,
that any such effect resulting from or arising out of (i) any change in Law or
United States generally accepted accounting principles (&#147;<u>U.S. GAAP</u>&#148;) or
interpretations thereof, (ii) economic or business conditions in the United
States generally, (iii) conditions generally affecting the pharmaceutical
industry or (iv) the execution and delivery of this Agreement or the
consummation of the transactions contemplated hereby shall not be considered
when determining if a Sicor Material Adverse Effect has occurred.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As used in this Agreement, the term &#147;<u>knowledge</u>&#148; or any similar
formulation of knowledge shall mean the knowledge, after due inquiry, of, with
respect to Sicor, those persons set forth in Section&nbsp;5.1(a) of Sicor
Disclosure Schedules and, with respect to Teva, those persons set forth in
Section&nbsp;5.2(a) of the disclosure schedules delivered to Sicor by Teva on
or prior to the date of this Agreement (the &#147;<u>Teva Disclosure Schedules</u>&#148;).</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Capital
Structure</u>.&#160; The authorized capital
stock of Sicor consists of (i) 250,000,000 shares of Sicor Common Stock, of
which 119,050,306 shares were outstanding as of October&nbsp;27, 2003 and (ii)
5,000,000 shares of preferred stock, par value $0.01 per share (the &#147;<u>Sicor
Preferred Stock</u>&#148;), of which 125,000 shares are designated Series I
Participating Preferred Stock (the &#147;<u>Series I Preferred Stock</u>&#148;), none of
which were outstanding as of the date hereof.&#160;
Pursuant to Sicor&#146;s Stockholder Rights Plan, dated March&nbsp;16, 1992,
as amended (the &#147;<u>Stockholder Rights Plan</u>&#148;), each share of Sicor Common
Stock has attached thereto a right</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='9',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(each a &#147;<u>Right</u>&#148; and
collectively, the &#147;<u>Rights</u>&#148;) to purchase one one-thousandth of a share of
Series I Preferred Stock at a price of $200.00 per one one-thousandth of a
share, subject to adjustment.&#160; All of
the issued and outstanding shares of Sicor Common Stock have been duly
authorized and are validly issued, fully paid and nonassessable.&#160; Each of the outstanding shares of capital
stock or other securities of each of Sicor&#146;s Subsidiaries is duly authorized,
validly issued, fully paid and nonassessable and is owned by Sicor or a direct
or indirect wholly-owned Subsidiary of Sicor, free and clear of any lien,
pledge, security interest, claim or other encumbrance.&#160; Except as set forth on Section&nbsp;5.1(b)
of the Sicor Disclosure Schedules and other than pursuant to (i) Sicor&#146;s 1997
Long-Term Incentive Plan, as amended, (ii) Sicor&#146;s 1992 Employee Stock Purchase
Plan, as amended, (iii) Sicor&#146;s 401(k) Employee Savings and Retirement Plan and
(iv) the Stockholder Rights Plan (collectively, the &#147;<u>Sicor Stock Plans</u>&#148;),
there are no preemptive or other outstanding rights, options, warrants,
conversion rights, stock appreciation rights, redemption rights, repurchase
rights, agreements, arrangements or commitments to issue or to sell any shares
of capital stock or other securities of Sicor or any of its Significant
Subsidiaries or any securities or obligations convertible or exchangeable into
or exercisable for, or giving any Person a right to subscribe for or acquire,
any securities of Sicor or any of its Significant Subsidiaries, and no
securities or obligations evidencing such rights are authorized, issued or
outstanding.&#160; Section&nbsp;5.1(b) of the
Sicor Disclosure Schedules set forth a complete and correct list, as of the
date of this Agreement, of the number of shares of Sicor Common Stock subject
to options or other rights to purchase or receive Sicor Common Stock granted
under the Sicor Stock Plans or otherwise, together with the dates of grant and
the exercise prices thereof.&#160; Except as
set forth on Section&nbsp;5.1(b) of the Sicor Disclosure Schedules, Sicor does
not have outstanding any bonds, debentures, notes or other obligations the
holders of which have the right to vote (or convertible into or exercisable for
securities having the right to vote) with the stockholders of Sicor on any
matter (&#147;<u>Voting Debt</u>&#148;).</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Corporate
Authority</u>.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sicor has all
requisite corporate power and authority and has taken all corporate action
necessary in order to execute, deliver and perform its obligations under this
Agreement and to consummate, on the terms and subject to the conditions of this
Agreement, the transactions contemplated hereby, subject only to receipt of the
Sicor Requisite Vote and the Sicor Required Statutory Approvals.&#160; This Agreement has been duly executed and
delivered by Sicor and, assuming due authorization, execution and delivery by
each of Teva and Merger Sub, is a valid and legally binding agreement of Sicor
enforceable against Sicor in accordance with its terms, subject to bankruptcy,
insolvency, fraudulent transfer, reorganization, moratorium and similar Laws of
general applicability relating to or affecting creditors&#146; rights and to general
equity principles (the &#147;<u>Bankruptcy and Equity Exception</u>&#148;).</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>As of the date
hereof, the Board of Directors of Sicor has approved and adopted this Agreement
and the Merger and other transactions contemplated hereby and, subject to
Section&nbsp;7.2, has resolved to recommend that the stockholders of Sicor
approve this Agreement and the transactions contemplated hereby.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='10',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Governmental
Filings; No Violations</u>.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except as set
forth on Section&nbsp;5.1(d)(i) of the Sicor Disclosure Schedules, other than
any reports, filings, registrations, approvals and/or notices (A) required to
be made pursuant to Section&nbsp;1.2, (B) under the Hart-Scott-Rodino Antitrust
Improvements Act of 1976, as amended (the &#147;<u>HSR Act</u>&#148;), the Securities Act
of 1933, as amended (the &#147;<u>Securities Act</u>&#148;), and the Exchange Act, (C)
the filings with or approvals from Governmental Entities required solely by
virtue of the jurisdictions in which Sicor or its Significant Subsidiaries
conduct business or own any assets under (1) <i><font style="font-style:italic;">Ley Federal de Competencia Economica </font></i>(Mexico)
and the regulations promulgated thereunder, (2) the Lithuanian Law on
Competition and (3) Brazilian merger control Law No. 8884/1994 (collectively,
the &#147;<u>Foreign Antitrust Filings</u>&#148;) and (D) to comply with the rules and
regulations of the National Association of Securities Dealers, Inc. (the
&#147;NASD&#148;) (items (B) through (D) (inclusive)), the &#147;<u>Sicor Required Statutory
Approvals</u>&#148;), no notices, reports, registrations or other filings are
required to be made by Sicor with, nor are any consents, registrations,
approvals, permits or authorizations required to be obtained by Sicor from, any
United States or foreign federal, state, or local governmental or regulatory
authority, agency, commission, body or other governmental entity including,
without limitation, the FDA (each a &#147;<u>Governmental Entity</u>&#148;), in
connection with the execution and delivery of this Agreement and the
consummation by Sicor of the transactions contemplated hereby (including
pursuant to the Stockholders Agreement), except for those that the failure to
make or obtain are not, individually or in the aggregate, reasonably likely to
have a Sicor Material Adverse Effect or prevent, materially delay or materially
impair the ability of Sicor to consummate the transactions contemplated by this
Agreement.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except as set forth
on Section&nbsp;5.1(d)(ii) of the Sicor Disclosure Schedules, the execution,
delivery and performance of this Agreement and the consummation by Sicor of the
transactions contemplated hereby (including pursuant to the Stockholders
Agreement) will not constitute or result in (A) a breach or violation of, or a
default under, either the certificate of incorporation or by-laws (or
comparable governing instruments) of Sicor or of any Significant Subsidiary of
Sicor, (B) a breach or violation of, a default under, the acceleration of any
obligations, the loss of any right or benefit, or the creation of a lien,
pledge, security interest or other encumbrance on the assets of Sicor or any
Subsidiary of Sicor (with or without notice, lapse of time or both) pursuant
to, any agreement, lease, contract, note, mortgage, indenture, arrangement or
other obligation not otherwise terminable by the other party thereto on ninety
(90) days or less notice (&#147;<u>Contracts</u>&#148;) binding upon Sicor or any
Subsidiary of Sicor or any Law or governmental or non-governmental permit or
license to which Sicor or any of its Subsidiaries is subject or (C) any change
in the rights or obligations of any party under any of the Contracts, except, in
the case of clause (B) or (C) above, for any breach, violation, default,
acceleration, creation or change that would not, individually or in the
aggregate, be reasonably likely to have a Sicor Material Adverse Effect or
prevent, or materially impair the ability of Sicor to consummate the
transactions contemplated by this Agreement.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Sicor
Reports; Financial Statements</u>.&#160; The
filings required to be made by Sicor since December&nbsp;31, 2000 under the
Securities Act and the Exchange Act have been filed with the</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='11',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Securities and Exchange
Commission (the &#147;<u>SEC</u>&#148;), including all forms, registration, proxy and
information statements, reports, agreements (oral or written) and all
documents, exhibits, amendments and supplements appertaining thereto, and
complied, as of their respective dates, in all material respects with all
applicable requirements of the appropriate statutes and the rules and
regulations thereunder (collectively, including any amendments of any such
reports filed with or furnished to the SEC by Sicor prior to the date hereof,
the &#147;<u>Sicor Reports</u>&#148;).&#160; Sicor has
made available to Teva (i) each Sicor Report filed with or furnished to the SEC
by Sicor pursuant to the Securities Act or the Exchange Act since
December&nbsp;31, 2000 and prior to the date hereof, each in the form
(including exhibits, annexes and any amendments thereto) promulgated by the SEC
under the Securities Act or the Exchange Act, as the case may be, and (ii) each
of Sicor&#146;s press releases released to the public in 2003 which are located at
http://investor.sicor.com/releases.cfm.&#160;
None of the Sicor Reports (in the case of Sicor Reports filed pursuant
to the Securities Act), as of their effective dates, contained any untrue
statement of a material fact or omitted to state a material fact required to be
stated therein or necessary to make the statements made therein not
misleading.&#160; None of the Sicor Reports
(in the case of Sicor Reports filed pursuant to the Exchange Act) as of the
respective dates filed with the SEC or first mailed to stockholders, as
applicable, contained any untrue statement of a material fact or omitted to
state any material fact necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading.&#160; None of the Sicor Reports (in the case of
Sicor Reports issued to the public as press releases) as of their respective
release dates, contained any untrue statement of a material fact or omitted to
state any material fact necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading.&#160; Except as set forth on Section&nbsp;5.1(e)
of the Sicor Disclosure Schedules, the consolidated financial statements of
Sicor and its Subsidiaries included in such Sicor Reports comply as to form in
all material respects with the applicable rules and regulations of the SEC with
respect thereto.&#160; Each of the
consolidated balance sheets included in or incorporated by reference into Sicor
Reports (including the related notes and schedules) presents fairly, in all
material respects, the financial position of Sicor and its Subsidiaries as of
its date, and each of the consolidated statements of income and consolidated
statements of cash flows included in or incorporated by reference into Sicor
Reports (including any related notes and schedules) fairly presents in all
material respects the results of operations, retained earnings and changes in
financial position, as the case may be, of Sicor and its Subsidiaries for the
periods set forth therein (subject, in the case of unaudited statements, to the
absence of notes and normal year-end audit adjustments), in each case in
accordance with U.S. GAAP consistently applied during the periods involved, except
as may be noted therein.&#160; Any change by
Sicor in the accounting principles, practices or methods used in such financial
statements of Sicor and its Subsidiaries included in the Sicor Reports has been
appropriately disclosed in such financial statements.&#160; Sicor&#146;s disclosure controls and procedures (as defined in
sections 13a-15(e) and 15d-15(e) of the Exchange Act) effectively enable Sicor
to comply with, and the appropriate officers of Sicor to make all certifications
required under, the Sarbanes-Oxley Act of 2002 and the regulations promulgated
thereunder (the &#147;<u>Sarbanes-Oxley Act</u>&#148;).</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Disclosure
Documents</u>.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The proxy
statement of Sicor (which will also constitute the prospectus of Teva) to be
filed with the SEC in connection with the Merger (the &#147;<u>Proxy</u></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='12',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Statement/Prospectus</font></u>&#148;) and any amendments or
supplements thereto will, when filed, comply as to form in all material
respects with the applicable requirements of the Exchange Act.&#160; At the time the Proxy Statement/Prospectus
or any amendment or supplement thereto is first mailed to stockholders of
Sicor, and at the time such stockholders vote on adoption of this Agreement,
the Proxy Statement/Prospectus, as supplemented or amended, if applicable, will
not contain any untrue statement of a material fact or omit to state any
material fact necessary in order to make the statements made therein, in the
light of the circumstances under which they were made, not misleading.&#160; The representations and warranties contained
in this Section&nbsp;5.1(f) will not apply to statements or omissions included
in the Proxy Statement/Prospectus based upon information furnished to Sicor in
writing by or on behalf of Teva specifically for use therein.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>None of the information
provided by Sicor for inclusion in the Registration Statement or any amendment
or supplement thereto, at the time the Registration Statement or any amendment
or supplement thereto becomes effective, will contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein
or necessary in order to make the statements made therein, in the light of the
circumstances under which they were made, not misleading.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No
Undisclosed Material Liabilities</u>.&#160;
Except as set forth on Schedule&nbsp;5.1(g) of the Sicor Disclosure
Schedules, there are no liabilities or obligations of Sicor or any of its
Subsidiaries of any kind whatsoever in existence on the date hereof, whether
accrued, contingent, absolute, determined, determinable or otherwise, other
than:&#160; (i)&#160; liabilities or obligations disclosed and provided for in the
Sicor balance sheet as of June&nbsp;30, 2003 included in the Sicor Reports or in
the notes thereto (the &#147;<u>Sicor Balance Sheet</u>&#148;) or in the Sicor Reports
filed prior to the date hereof; (ii) liabilities or obligations incurred in the
ordinary course of business consistent with past practices since June&nbsp;30,
2003; (iii) liabilities and obligations not required to be disclosed on the
Sicor Balance Sheet under U.S. GAAP; and&#160;
(iv)&#160; liabilities or obligations
that would not reasonably be expected to have, individually or in the
aggregate, a Sicor Material Adverse Effect.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Absence
of Certain Changes</u>.&#160; Except as
described in the Sicor Reports or as set forth on Schedule&nbsp;5.1(h) of the
Sicor Disclosure Schedules, since December&nbsp;31, 2002 (the &#147;<u>Audit Date</u>&#148;),
except as expressly contemplated by this Agreement, Sicor and its Subsidiaries
taken as a whole have conducted their business only in, and have not engaged in
any material transaction other than according to, Sicor&#146;s ordinary and usual
course of such business and there has not been (i) any change in the financial
condition, properties, assets, business or results of operations of Sicor and
its Subsidiaries that has had or would be reasonably likely to have a Sicor
Material Adverse Effect; (ii) any declaration, setting aside or payment of any
dividend or other distribution in respect of the capital stock of Sicor or any
repurchase, redemption or other acquisition by Sicor or any Subsidiary of any
securities of Sicor or (iii) any change by Sicor in accounting principles,
practices or methods which is not required or permitted by U.S. GAAP.&#160; Since the Audit Date and through the date
hereof, except as provided for herein, there has not been any material increase
in the compensation payable or that could become payable by Sicor or any of its
Significant Subsidiaries to officers or key employees or any material amendment
of</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='13',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">any of the Compensation and
Benefit Plans other than increases or amendments in the ordinary course of
business consistent with past practice.&#160;
Except as disclosed in the Sicor Reports, since January&nbsp;1, 2003,
there have not been any changes, circumstances or events which, individually or
in the aggregate, have had, or would reasonably be expected to have, a Sicor
Material Adverse Effect.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Litigation</u>.&#160; Except as described in the Sicor Reports or
as set forth on Schedule&nbsp;5.1(i) of the Sicor Disclosure Schedules, there
are no civil, criminal or administrative actions, suits, claims, hearings,
investigations, reviews or proceedings pending or, to the knowledge of Sicor,
threatened against Sicor or any of its Subsidiaries, except for those that
would not be reasonably likely to have, either individually or in the
aggregate, a Sicor Material Adverse Effect.&#160;
There are no material SEC inquiries or investigations, other material
governmental inquiries or investigations or material internal investigations
pending, or to the knowledge of Sicor, threatened, in each case regarding any
accounting practices of Sicor or any of its Subsidiaries or any malfeasance by
any director or executive officer of Sicor or any of its Subsidiaries.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Employee
Benefits</u>.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The term &#147;<u>Compensation
and Benefit Plan</u>&#148; shall mean any bonus, deferred compensation, pension,
retirement, profit-sharing, thrift, savings, employee stock ownership, stock
bonus, stock purchase, change in control, retention, restricted stock, stock
option, employment, termination, severance, compensation, medical, health or
other compensation or benefit plan, including, without limitation, each
&#147;employee benefit plan&#148; within the meaning of Section&nbsp;3(3) of the Employee
Retirement Income Security Act of 1974, as amended (&#147;<u>ERISA</u>&#148;), that
covers employees or former employees (&#147;<u>Employees</u>&#148;), or directors or
former directors of a party, or to which contributions are made or otherwise
required to be made; and any trust agreement or insurance contract forming a
part of such Compensation and Benefit Plan.&#160;
Section&nbsp;5.1(j) of the Sicor Disclosure Schedules lists all
Compensation and Benefit Plans of Sicor and its Subsidiaries (&#147;<u>Sicor
Compensation and Benefit Plans</u>&#148;), and any Sicor Compensation and Benefit
Plans containing &#147;change of control&#148; or similar provisions therein are
specifically identified in Section&nbsp;5.1(j) of the Sicor Disclosure
Schedules.&#160; Sicor has made available to
Teva prior to the date hereof a copy of all Sicor Compensation and Benefit
Plans and a copy of each agreement, policy, practice or arrangement that covers
key employees or former key employees of Sicor and its Significant
Subsidiaries.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All Sicor
Compensation and Benefit Plans, to the extent subject to ERISA and the Code,
are in compliance with the applicable provisions of ERISA, the Code and any
other applicable Law.&#160; Each Sicor
Compensation and Benefit Plan that is an &#147;employee pension benefit plan&#148; within
the meaning of Section&nbsp;3(2) of ERISA (a &#147;<u>Pension Plan&#148;</u>) and that is
intended to be qualified under Section&nbsp;401(a) of the Code has received a
favorable determination letter from the U.S. Department of the Treasury,
Internal Revenue Service (the &#147;<u>IRS</u>&#148;), and nothing has occurred, whether
by action or failure to act, that would cause the loss of such qualification or
that would result in costs to Sicor or any of its Subsidiaries under the
Internal Revenue Service&#146;s Employee Plans</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='14',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Compliance Resolution System.&#160;
There is no pending or, to the knowledge of Sicor, threatened litigation
or other proceeding relating to the Sicor Compensation and Benefit Plans.&#160; Neither Sicor nor any of its Subsidiaries
has engaged in a transaction with respect to any Pension Plan that, assuming
the taxable period of such transaction expired as of the date hereof, would
subject Sicor or any of its Subsidiaries to a tax or penalty imposed by either
Section&nbsp;4975 of the Code or Section&nbsp;502(i) of ERISA.</font></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>No liability under
Subtitle C or D of Title IV of ERISA has been or is expected to be incurred by
Sicor or any of its Subsidiaries with respect to any ongoing, frozen or
terminated &#147;single-employer plan,&#148; within the meaning of
Section&nbsp;4001(a)(15) of ERISA, currently or formerly maintained by any of
them, or the single-employer plan of any entity which is considered one
employer with Sicor under Section&nbsp;4001 of ERISA or Section&nbsp;414 of the
Code (an &#147;<u>ERISA Affiliate</u>&#148;).&#160;
Sicor and its Subsidiaries have not incurred and do not expect to incur
any withdrawal liability with respect to a multi-employer plan under Subtitle E
of Title IV of ERISA (regardless of whether based on contributions of an ERISA
Affiliate).&#160; No notice of a &#147;reportable
event,&#148; within the meaning of Section&nbsp;4043 of ERISA for which the thirty
(30) day reporting requirement has not been waived or extended, other than an
extension pursuant to Pension Benefit Guaranty Corporation Reg.
Section&nbsp;4043.66, has been required to be filed for any Sicor Pension Plan
or by any ERISA Affiliate within the twelve (12) month period ending on the
date hereof.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All contributions
required to be made under the terms of any Sicor Compensation and Benefit Plan
subject to United States law have been timely made or have been reflected on
the most recent consolidated balance sheet filed or incorporated by reference
in Sicor Reports. Neither any Pension Plan nor any single-employer plan of an
ERISA Affiliate has an &#147;accumulated funding deficiency&#148; (whether or not waived)
within the meaning of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA
and no ERISA Affiliate has an outstanding funding waiver.&#160; Neither Sicor nor any of its Subsidiaries
has provided, or is required to provide, security to any Pension Plan subject
to United States law or to any single-employer plan of an ERISA Affiliate
pursuant to Section&nbsp;401(a)(29) of the Code.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Neither Sicor nor its
Subsidiaries have any obligations for, or liabilities with respect to, retiree
health and life benefits under any Sicor Compensation and Benefit Plan subject
to United States law, except for benefits required to be provided under
Section&nbsp;4980B of the Code or any other applicable law requiring
continuation of health coverage.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Neither the negotiation
and execution of this Agreement nor the consummation of the transactions
contemplated hereby (including pursuant to the Stockholders Agreement) will
(either alone or upon the occurrence of any additional or subsequent events)
constitute an event under any Sicor Compensation and Benefit Plan that will or
may result in any payment (whether of severance pay or otherwise), acceleration
of payment, forgiveness of indebtedness, vesting, distribution, increase in
benefits or obligation to fund benefits with respect to any employee or former
employee</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='15',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of Sicor or any of its Subsidiaries.&#160;
There is no contract, agreement, plan or arrangement with an employee or
former employee of Sicor or any of its Subsidiaries to which Sicor or any of
its Subsidiaries is a party as of the date of this Agreement that, individually
or collectively and as a result of the transactions contemplated hereby
(including pursuant to the Stockholders Agreement), whether alone or upon the
occurrence of any additional or subsequent events, or otherwise, would
reasonably be likely to give rise to the payment of any amount that would not
be deductible pursuant to Sections 280G or 162(m) of the Code.</font></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>With respect to each Sicor
Compensation and Benefit Plan not subject to United States law (a &#147;<u>Sicor
Foreign Benefit Plan</u>&#148;):&#160; (i) each
Sicor Foreign Benefit Plan is in compliance with applicable Law; (ii) each
Sicor Foreign Benefit Plan required to be registered with a regulatory agency
or authority has been registered and has been maintained in good standing with
such agency or authority, and (iii) as of the Effective Time, the fair market
value of the assets of each Sicor Foreign Benefit Plan is sufficient to provide
for the accrued benefit obligations with respect to all current and former
participants in such plan according to the actuarial assumptions and valuations
most recently used to determine employer contributions to such Sicor Foreign
Benefit Plan.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(viii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Notwithstanding anything to the
contrary contained in this Section&nbsp;5.1(j), the representations and
warranties contained in this Section&nbsp;5.1(j) shall be deemed to be true and
correct unless such failures to be true and correct are reasonably likely to
have a Sicor Material Adverse Effect.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(k)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Compliance
with Laws</u>.&#160; The&#160; business of Sicor and its Subsidiaries is
not being conducted in violation of any United States or foreign, federal,
state or local law, statute, ordinance, rule, regulation, judgment, order,
injunction, decree, arbitration award, agency requirement, license or permit of
any Governmental Entity (collectively, &#147;<u>Laws</u>&#148;), including United States
Food and Drug Administration (&#147;<u>FDA</u>&#148;) and other Governmental Entity
rules, regulations and policies relating to good clinical practices, good
manufacturing practices, good laboratory practices, advertising and promotion,
pre- and post-marketing adverse drug experience and adverse drug reaction
reporting, and all other pre- and post-marketing reporting requirements, as
applicable, except for violations that would not be reasonably likely to have,
either individually or in the aggregate, a Sicor Material Adverse Effect or
prevent or materially impair the ability of Sicor to consummate the
transactions contemplated by this Agreement.&#160;
Sicor is not debarred under the Generic Drug Enforcement Act of 1992 and
does not employ or use the services of any individual who is debarred or, to
the best of Sicor&#146;s knowledge, has engaged in any activity that could lead to
debarment.&#160; Except as set forth on
Section&nbsp;5.1(k) of the Sicor Disclosure Schedules, no investigation or
review by any Governmental Entity with respect to Sicor or any of its
Subsidiaries is pending or, to the knowledge of Sicor, threatened, nor has any
Governmental Entity indicated in writing an intention to conduct the same,
except for those the outcome of which would not be reasonably likely to have,
either individually or in the aggregate, a Sicor Material Adverse Effect or
prevent or materially impair the ability of Sicor to consummate the
transactions contemplated by this Agreement.&#160;
Sicor and each of its Subsidiaries has, or has applied for, all permits,
licenses, franchises, variances, exemptions, orders and other</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='16',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">governmental authorizations,
consents and approvals from Governmental Entities necessary to conduct its business
as currently conducted, except for those the absence of which would not be
reasonably likely to have, either individually or in the aggregate, a Sicor
Material Adverse Effect or prevent or materially impair the ability of Sicor to
consummate the transactions contemplated by this Agreement.&#160; The provisions of this Section&nbsp;5(k)
shall not apply to Environmental Laws which are covered exclusively in
Section&nbsp;5.1(m).</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(l)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Anti-takeover
Statutes and Rights Agreement</u>.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sicor has taken
all action necessary to exempt the Merger, this Agreement, the Stockholders
Agreement and the transactions contemplated hereby and thereby from the
provisions of Section&nbsp;203 of the DGCL.&#160;
No other state anti-takeover statute or regulation is applicable to this
Agreement, the Stockholders Agreement and the transactions contemplated hereby
and thereby.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sicor has taken all
action necessary to render the Stockholder Rights Plan inapplicable to the
Merger, the Stockholders Agreement and the transactions contemplated hereby and
thereby.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(m)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Environmental
Matters</u>.&#160; Except as set forth on
Section&nbsp;5.1(m) of the Sicor Disclosure Schedules and except for such
matters that would not, either individually or in the aggregate, be reasonably
likely to cause a Sicor Material Adverse Effect:&#160; (i) the operations of Sicor and its Subsidiaries are and have
been in compliance with all applicable Environmental Laws; (ii) each of Sicor
and its Subsidiaries possesses and maintains in effect all environmental
permits, licenses, authorizations and approvals required under applicable
Environmental Laws with respect to the properties and business of Sicor and its
Subsidiaries; (iii) neither Sicor nor any of its Subsidiaries have received any
written environmental claim, notice or request for information concerning any
violation or alleged violation of any applicable Environmental Law, nor, to
Sicor&#146;s knowledge, is there any existing factual or legal basis for any such
claim, notice or request for information; (iv) neither Sicor nor any of its
Subsidiaries has any knowledge of a release or threat of release of any
Hazardous Substances which could reasonably be expected to result in liability
to Sicor or any of it Subsidiaries at any of its or any of its Subsidiaries&#146;
current or former properties or at any other property arising from its or any
of its Subsidiaries&#146; current or former operations; (v) there are no writs,
injunctions, decrees, orders or judgments outstanding, or any actions, suits or
proceedings pending relating to compliance by Sicor or any of its Subsidiaries
with any environmental permits, licenses, authorizations and approvals required
under applicable Environmental Laws or liability of Sicor or any of its
Subsidiaries under any applicable Environmental Law; and (vi) no Lien has been
placed upon any of Sicor&#146;s or the Subsidiaries&#146; properties (whether owned,
leased or managed) under any Environmental Law.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding any other provision of this Agreement to the contrary
(including, but not limited to, Section&nbsp;5.1(k)), the representations and
warranties of Sicor in this Section&nbsp;5.1(m) constitute the sole
representations and warranties of Sicor with respect to any Environmental Law
or Hazardous Substance.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='17',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As used herein, the term &#147;<u>Asbestos</u>&#148; includes chrysotile,
amosite, crocidolite; tremolite asbestos, anthophyllite asbestos, actinolite
asbestos, asbestos winchite, asbestos richterite, and any of these minerals
that have been chemically treated and/or altered and any asbestiform variety, type
or component thereof and any asbestos-containing material.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As used herein, the term &#147;<u>Asbestos-Containing Material</u>&#148; means
any material containing Asbestos, including, without limitation, any
Asbestos-containing products, automotive or industrial parts or components,
equipment, improvements to real property and any other material that contains
Asbestos in any chemical or physical form.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As used herein, the term &#147;<u>Environmental Law</u>&#148; means any Law
(including common law) relating to:&#160; (a)
pollution; (b) the protection of the environment (including air, water, soil,
subsurface strata and natural resources) or human health and safety; and (c)
the regulation of the generation, use, storage, handling, transportation,
treatment, release, remediation or disposal of Hazardous Substances.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As used herein, the term &#147;<u>Hazardous Substance</u>&#148; means any
chemical, material or substance that is potentially harmful to human health,
the environment, or natural</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>resources or defined as such by any
Environmental Law, including without limitation, petroleum, petroleum products,
Asbestos, and Asbestos-Containing Materials.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(n)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Tax
Matters</u>.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sicor and each of
its Subsidiaries (A) have duly and timely filed (taking into account any
extension of time within which to file) all material Tax Returns required to be
filed by any of them as of the date hereof and all such filed Tax Returns are
complete and accurate in all material respects; (B) (I) have timely paid all
Taxes that are shown as due on such filed Tax Returns or that Sicor or any of
its Subsidiaries are obligated to pay without the filing of a Tax Return,
except with respect to Taxes that are being contested in good faith, and (II)
no material penalties or charges are due with respect to the late filing of any
Tax Return required to be filed by or with respect to any of them on or before
the Effective Time; (C) with respect to all material Tax Returns filed by or
with respect to any of them, have not waived any statute of limitations with
respect to Taxes or agreed to any extension of time with respect to a Tax
assessment or deficiency; (D) except as set forth on Section&nbsp;5.1(n) of the
Sicor Disclosure Schedules, as of the date hereof, do not have any deficiency,
audit, examination, investigation or other proceeding in respect of Taxes or
Tax matters pending or proposed or threatened in writing; and (E) have provided
adequate reserves in the most recent consolidated financial statements of Sicor
and its Subsidiaries, as disclosed in the Sicor Reports, for any material Taxes
of Sicor on any of its Subsidiaries that have not been paid, whether or not
shown as being due on any Tax Returns.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>None of Sicor and its
Subsidiaries is party to any Tax allocation, indemnification or sharing
agreement.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>None of Sicor and its
Subsidiaries will be required to include any material item of income in, or
exclude any material item of deduction from, taxable</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='18',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">income for any taxable period (or portion thereof) ending after the
Closing Date as a result of any:&#160; (A)
change in method of accounting for a taxable period ending on or prior to the
Closing Date under Code Section&nbsp;481(c) (or any corresponding or similar
provision of state, local or foreign income Tax law); (B) &#147;closing agreement&#148;
as described in Code Section&nbsp;7121 (or any corresponding or similar
provision of state, local or foreign income Tax law) executed on or prior to
the Closing Date; or (C) installment sale or intercompany transaction (as
defined in Treasury regulations section&nbsp;1502-13) made on or prior to the
Closing Date.</font></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each of Sicor and its
Subsidiaries has withheld and paid all material Taxes required to have been
withheld and paid in connection with amounts paid or owing to any current or
former employee, independent contractor, creditor, stockholder or other third
party.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Neither Sicor nor any
of its Subsidiaries has been a member of an affiliated group filing a
consolidated, combined or unitary U.S. federal, state, local or foreign income
Tax Return (other than a group whose common parent was Sicor).</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Neither Sicor nor any of
its Subsidiaries has any material liability for the Taxes of any person (other
than Sicor and its Subsidiaries) under Treasury regulation
section&nbsp;1.1502-6 (or any similar provision of state, local, or foreign
law), as a transferee or successor, by contract, or otherwise.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Neither Sicor nor any of its
Subsidiaries has any requests for material rulings in respect of Taxes pending
between Sicor or any Subsidiary and any Tax authority.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(viii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sicor has made available to
Teva true and correct copies of the U.S. federal income Tax Returns filed by
Sicor and its Subsidiaries for tax years 2000 through 2002.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ix)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>There is no contract or
agreement, plan or arrangement by Sicor or its Subsidiaries covering any Person
that, individually or collectively, would constitute compensation in excess of
the deduction limitation set forth in Section&nbsp;162(m) of the Code.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(x)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>As used in this
Agreement, (i) the term &#147;<u>Tax</u>&#148; (including, with correlative meaning, the
terms &#147;<u>Taxes</u>,&#148; and &#147;<u>Taxable</u>&#148;) includes all federal, state, local
and foreign income, profits, franchise, gross receipts, environmental, customs
duty, capital stock, severances, stamp, payroll, sales, employment,
unemployment, disability, use, property, withholding, excise, production, value
added, occupancy and other taxes, duties or assessments of any nature
whatsoever, together with all interest, penalties and additions imposed with
respect to such amounts and any interest in respect of such penalties and
additions, and (ii) the term &#147;<u>Tax Return</u>&#148; includes all returns and
reports (including elections, declarations, disclosures, schedules, estimates
and information returns, as well as attachments thereto and amendments thereof)
required to be supplied to a Tax authority relating to Taxes.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='19',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(o)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Labor
Matters</u>.&#160; Except as set forth on
Section&nbsp;5.1(o) of the Sicor Disclosure Schedules, neither Sicor nor any of
its Subsidiaries is the subject of any material proceeding asserting that Sicor
or any of its Subsidiaries has committed an unfair labor practice or any other
violation of law relating to employee matters, nor since January&nbsp;1, 2003
has there been any labor strike, dispute, walk-out, work stoppage, slow-down or
lockout involving Sicor or any of its Subsidiaries, except for those that,
either individually or in the aggregate, are not reasonably likely to have a
Sicor Material Adverse Effect.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(p)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Intellectual
Property</u>.&#160; Except as described in
the Sicor Reports or on Section&nbsp;5.1(p) of the Sicor Disclosure Schedules,</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sicor or one of
its Subsidiaries owns, or is licensed or otherwise possesses sufficient legally
enforceable rights to use, all patents, trademarks, trade names, service marks,
copyrights, technology, know-how, computer software programs or applications,
databases and tangible or intangible proprietary information or materials that
are currently used in its and its Subsidiaries&#146; businesses (collectively, &#147;<u>Sicor
Intellectual Property Rights</u>&#148;), except for any such failures to own, be
licensed or possess that, individually or in the aggregate, are not reasonably
likely to have a Sicor Material Adverse Effect.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except for such
matters that, individually or in the aggregate, are not reasonably likely to
have a Sicor Material Adverse Effect, (A) the use of Sicor Intellectual
Property Rights by Sicor or its Subsidiaries does not conflict with, infringe
upon, violate or interfere with or constitute an appropriation of any right,
title, interest or goodwill, including, without limitation, any valid patent,
trademark, trade name, service mark, copyright or other valid intellectual
property right of any other Person and (B) there have been no claims made and
neither Sicor nor any of its Subsidiaries has received written notice of any
claim or otherwise knows that any Sicor Intellectual Property Right is invalid,
or conflicts with the asserted right of any other Person.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(q)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Title
to Properties</u>.&#160; Except as set forth
on Section&nbsp;5.1(q) of the Sicor Disclosure Schedules, Sicor and each of its
Subsidiaries has good and valid title to all of its material properties and
assets, free and clear of all mortgages, liens, pledges, charges, security
interests, encumbrances or other adverse claims of any kind in respect of such
property or asset (collectively, &#147;<u>Liens</u>&#148;), except Liens for taxes not
yet due and payable and such Liens or other imperfections of title, if any,
that, individually or in the aggregate, are not reasonably likely to have a
Sicor Material Adverse Effect.&#160; All
leases pursuant to which Sicor and each of its Subsidiaries leases from others
material real or personal property are valid and effective in accordance with
their respective terms, and there is not, under any of such leases, any
existing&#160; default or event of default of
Sicor or any of its Subsidiaries or, to the knowledge of Sicor, any other party
(or any event which with notice or lapse of time, or both, would constitute a
material default), that, individually or in the aggregate, are reasonably
likely to have a Sicor Material Adverse Effect.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(r)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Contracts</u>.&#160; Neither Sicor nor any of its Subsidiaries
has breached, or received in writing any claim or notice that it has breached,
any of the terms and conditions of any Contract</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='20',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">to which it is a party or by
which it is bound in such a manner as, individually or in the aggregate, are
reasonably likely to have a Sicor Material Adverse Effect.&#160; Each Contract to which Sicor or any of its
Subsidiaries is a party or by which it is bound that has not expired or
terminated by its terms is in full force and effect, except where the failure
to be in full force and effect, individually or in the aggregate, is not
reasonably likely to have a Sicor Material Adverse Effect.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(s)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Product
Liability</u>.&#160; Except as set forth on
Section&nbsp;5.1(s) of the Sicor Disclosure Schedules, no product liability
claims have been asserted in writing against Sicor or any of its Subsidiaries
or, to the knowledge of Sicor, threatened against Sicor or any of its
Subsidiaries relating to any or their products or product candidates developed,
tested, manufactured, marketed, distributed or sold by Sicor or any of its
Subsidiaries, except for claims that, individually or in the aggregate, are not
reasonably likely to have a Sicor Material Adverse Effect.&#160; There is no judgment, order or decree
outstanding against Sicor or any of its Subsidiaries relating to product
liability claims or assessments.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(t)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Insurance</u>.&#160; Sicor maintains for itself and its
Subsidiaries insurance policies covering the assets, business, equipment,
properties, operations, employees, directors and officers, and product warranty
and liability claims, and such other forms of insurance in such amounts, with
such deductibles and against such risks and losses as, in its judgment, are
reasonable for the business and assets of Sicor and its Subsidiaries.&#160; All such insurance policies are in full
force and effect, all premiums due and payable thereon have been paid, and
Sicor and its Subsidiaries are otherwise in compliance with the terms and
conditions of such policies and bonds except for failures to so comply that,
individually or in the aggregate, are not reasonably likely to have a Sicor
Material Adverse Effect.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(u)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Vote
Required</u>.&#160; The approval of the
majority of the shares of Sicor Common Stock outstanding on the record date for
such vote (the &#147;<u>Sicor Requisite Vote</u>&#148;) is the only vote of any class or
series of the capital stock of Sicor required to approve this Agreement, the Stockholders
Agreement and the transactions contemplated hereby and thereby.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Suppliers</u>.&#160; Sicor and its Subsidiaries has good
commercial relationships with each of its suppliers of active ingredients, bulk
chemical products and finished drug products and, to the best of its knowledge,
there are no facts concerning such suppliers that would reasonably be expected
to result in any material interruption in the timely supply by such suppliers
to Sicor and its Subsidiaries of any such materials, except as, individually or
in the aggregate, are not reasonably likely to have a Sicor Material Adverse
Effect.&#160; No such supplier has notified
Sicor or its Subsidiaries in writing that it intends to terminate or materially
alter the terms of its supply relationship with Sicor and its Subsidiaries,
except as, individually or in the aggregate with all other such notifications,
is not reasonably likely to have a Sicor Material Adverse Effect.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(w)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Transactions
with Affiliates</u>.&#160; Except as
disclosed on Section&nbsp;5.1(w) of the Sicor Disclosure Schedules or in the
Sicor Reports, no present or former affiliate of Sicor has, or since
December&nbsp;31, 2001 has had, (i) any interest in any property (whether real,
personal or mixed and whether tangible or intangible) used in or pertaining to
any of the businesses of Sicor or any of its Subsidiaries, (ii) has had
business dealings or a material financial interest in any transaction</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='21',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">with Sicor or any of its
Subsidiaries (other than compensation and benefits received in the ordinary
course of business as an employee or director of Sicor or any of its
Subsidiaries) or (iii) any material equity interest or any other material
financial or profit interest in any Person that has had business dealings or a
material financial interest in any transaction with Sicor or any of its
Subsidiaries.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(x)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Brokers
and Finders</u>.&#160; Except for Bear,
Stearns &amp; Co. Inc. (&#147;<u>Bear Stearns</u>&#148;), neither Sicor nor any of its
officers, directors or employees has retained any broker or finder or incurred
any liability for any brokerage fees, commissions or finders&#146; fees in
connection with the Merger, this Agreement, the Stockholders Agreement and the
transactions contemplated hereby and thereby.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(y)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Opinion
of Financial Advisor</u>.&#160; Sicor has
received an opinion of Bear Stearns, dated as of the date hereof, to the effect
that, as of such date, the Merger Consideration is fair from a financial point
of view to holders of shares of Sicor Common Stock.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(z)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No
Other Representations or Warranties</u>.&#160;
Except for the representations and warranties contained in this
Section&nbsp;5.1, neither Sicor nor any other Person makes any other express or
implied representation or warranty on behalf of Sicor or any of its Subsidiaries.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="RepresentationsandWarrantiesofTevaa25"><u>Representations and Warranties of
Teva a</u></a><u>nd Merger Sub</u>.&#160;
Teva and Merger Sub each represents and warrants to Sicor that:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Organization,
Good Standing and Qualification</u>.&#160;
Each of Teva and Merger Sub is a corporation and is duly organized,
validly existing and in good standing under the Laws of its respective
jurisdiction of organization.&#160; Each of
Teva and Merger Sub has all requisite corporate power to own and operate its
material properties and assets and to carry on its business as currently
conducted in all material respects and is qualified to do business and is in
good standing as a foreign corporation in each jurisdiction where the ownership
or operation of its properties and assets or conduct of its business requires
such qualification, except where the failure to be so qualified as a foreign
corporation or be in good standing would not be reasonably likely to have,
either individually or in the aggregate, a Teva Material Adverse Effect.&#160; Teva has made available to Sicor a complete
and correct copy of the Memorandum of Association and Articles of Association
of Teva and the certificate of incorporation and by-laws of Merger Sub, each as
amended through the date hereof and as in full force and effect on the date
hereof.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As used in this Agreement, the term &#147;<u>Teva Material Adverse Effect</u>&#148;
means a material adverse effect on the financial condition, business, assets or
results of operations of Teva and its Subsidiaries taken as a whole; <i><font style="font-style:italic;">provided,
however</font></i>, that any such effect resulting from or arising out of (i)
any change in Law or U.S. GAAP or interpretations thereof, (ii) economic or
business conditions in the United States generally, (iii) conditions generally
affecting the pharmaceutical industry or (iv) the execution and delivery of
this Agreement, or the contemplated consummation of the transactions
contemplated hereby, shall not be considered when determining if a Teva
Material Adverse Effect has occurred.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Capital
Structure</u>.&#160; The authorized share
capital of Teva consists of 999,575,693 ordinary shares, 424,247 class &#147;A&#148;
ordinary shares and 60 deferred shares, of which 277,108,725</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='22',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva Ordinary Shares, including
199,231,374 Teva Ordinary Shares represented by 199,231,374 outstanding Teva
ADSs, were outstanding as of the close of business on October&nbsp;29,
2003.&#160; One Teva ADS represents one Teva
Ordinary Share.&#160; All of the issued and
outstanding Teva Ordinary Shares and Teva ADSs have been, and all Teva ADSs
representing Teva Ordinary Shares which are to be issued pursuant to the Merger
have been duly authorized and will be, when issued in accordance with the terms
of this Agreement, validly issued, fully paid and nonassessable and are not
subject to any preemptive or similar right. Each of the outstanding shares of
capital stock, ownership interests,&#160; or
other securities of each of the Teva&#146;s Significant Subsidiaries (including
without limitation the shares of capital stock of Merger Sub) is duly
authorized, validly issued, fully paid and nonassessable and is owned by Teva
or a direct or indirect wholly-owned Subsidiary of Teva, free and clear of any
lien, pledge, security interest, claim or other encumbrance.&#160; Except pursuant to Teva&#146;s stock plans
(collectively, the &#147;<u>Teva Stock Plans</u>&#148;), as set forth on Section&nbsp;5.2(b)
of the Teva Disclosure Schedules, and except as otherwise set forth on
Section&nbsp;5.2(b) of the Teva Disclosure Schedules, there are no preemptive
or other outstanding rights, options, warrants, conversion rights, stock
appreciation rights, redemption rights, repurchase rights, agreements,
arrangements or commitments to issue or to sell any shares of capital stock,
ownership interests or other securities of Teva or any of its Significant
Subsidiaries or any securities or obligations convertible or exchangeable into
or exercisable for, or giving any Person a right to subscribe for or acquire,
any securities of Teva or any of its Significant Subsidiaries, and so
securities or obligations evidencing such rights authorized, issued or
outstanding.&#160; Except as set forth on
Section&nbsp;5.2(b) of the Teva Disclosure Schedules, Teva does not have
outstanding any Voting Debt.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Corporate
Authority</u>.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each of Teva and
Merger Sub has all requisite corporate power and authority and has taken all
corporate action necessary in order to execute, deliver and perform its
obligations under this Agreement and to consummate the transactions
contemplated hereby, subject only to receipt of the Teva Required Statutory
Approvals.&#160; This Agreement has been duly
executed and delivered by Teva and Merger Sub and, assuming due authorization,
execution and delivery by Sicor, is a valid and legally binding agreement of
Teva and Merger Sub, enforceable against each of Teva and Merger Sub in
accordance with its terms, subject to the Bankruptcy and Equity Exception.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Boards of
Directors of Teva and Merger Sub have approved and adopted this Agreement and
the Merger and the other transactions set forth herein.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Governmental
Filings; No Violations</u>.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Other than any
reports, filings, registrations, approvals and/or notices (A) required to be
made pursuant to Section&nbsp;1.2, (B) required to be made under the HSR Act,
the Securities Act and the Exchange Act and state securities and &#147;blue sky&#148;
laws, (C) required to be made with the Israeli Securities Authority (&#147;ISA&#148;),
(D) required to be made with the Tel Aviv Stock Exchange Ltd. (&#147;TASE&#148;), (E)
required to be made with Nasdaq and (F) the Foreign Antitrust Filings (items
(B) through (F) (inclusive)), the</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='23',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Teva Required Statutory Approvals&#148;), no notices, reports,
registrations or other filings are required to be made by Teva or Merger Sub
with, nor are any consents, registrations, approvals, permits or authorizations
required to be obtained by Teva or Merger Sub from, any Governmental Entity, in
connection with the execution and delivery by Teva and Merger Sub of this
Agreement and the consummation by Teva and Merger Sub of the Merger and the
other transactions contemplated hereby, except for those that the failure to
make or obtain would not be reasonably likely to have, either individually or
in the aggregate, a Teva Material Adverse Effect or prevent, materially delay
or materially impair the ability of Teva or Merger Sub to consummate the transactions
contemplated hereby.</font></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The execution,
delivery and performance of this Agreement by Teva and Merger Sub do not, and
the consummation by Teva and Merger Sub of the Merger and the other
transactions contemplated hereby will not, constitute or result in (A) breach
or violation of, or a default under, either the Memorandum of Association or
Articles of Association of Teva or the certificate of incorporation or by-laws
of Merger Sub or similar governing documents of any of Teva&#146;s Significant Subsidiaries,
(B) a breach or violation of, or a default under, the acceleration of any
obligations, the loss of any right or benefit or the creation of a lien,
pledge, security interest or other encumbrance on the assets of Teva, Merger
Sub or any of Teva&#146;s Subsidiaries (with or without notice, lapse of time or
both) pursuant to any Contracts binding upon Teva, Merger Sub or any of Teva&#146;s
Significant Subsidiaries or any Law or governmental or non-governmental permit
or license to which Teva, Merger Sub or any of Teva&#146;s Subsidiaries is subject
or (C) any change in the rights or obligations of any party under any of the
Contracts, except, in the case of clause (B) or (C) above, for any breach,
violation, default, acceleration, creation or change that would not be
reasonably likely to have, either individually or in the aggregate, a Teva
Material Adverse Effect or prevent, materially delay or materially impair the
ability of Teva or Merger Sub to consummate the transactions contemplated
hereby.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Teva
Reports; Financial Statements</u>.&#160; The
filings required to be made by Teva and, to the extent applicable, its
Subsidiaries since December&nbsp;31, 2000 under the Securities Act and the
Exchange Act have been filed with the SEC, including all forms, statements,
reports, agreements (oral or written) and all documents, exhibits, amendments
and supplements appertaining thereto, and complied, as of their respective
dates, in all material respects with all applicable requirements of the
appropriate statutes and the rules and regulations thereunder (collectively,
including any amendments of any such reports filed with or furnished to the SEC
by Teva prior to the date hereof, the &#147;<u>Teva Reports</u>&#148;).&#160; Teva has made available to Sicor (i) each
Teva Report filed with or furnished to the SEC by Teva pursuant to the
Securities Act or the Exchange Act since December&nbsp;31, 2000, and prior to
the date hereof, each in the form (including exhibits, annexes and any
amendments thereto) promulgated by the SEC under the Securities Act or the Exchange
Act, as the case may be and (ii) each of Teva&#146;s press releases released to the
public in 2003 which are located at
http://www.Tevapharm.com/pr/2003/index.asp.&#160;
None of the Teva Reports (in the case of Teva Reports filed pursuant to
the Securities Act), as of their effective dates, contained any untrue
statement of a material fact or omitted to state a material fact required to be
stated therein or necessary to make the statements made therein not</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='24',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">misleading. None of the Teva
Reports (in the case of Teva Reports filed pursuant to the Exchange Act) as of
the respective dates first mailed to stockholders, as applicable, contained any
untrue statement of a material fact or omitted to state any material fact necessary
in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading.&#160;
None of the Teva Reports (in the case of Teva Reports issued to the
public as press releases) as of their respective release dates, as applicable,
contained any untrue statement of a material fact or omitted to state any
material fact necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading.&#160; The consolidated financial statements of the
Teva and its Subsidiaries included in such Teva Reports comply as to form in
all material respects with the applicable rules and regulations of the SEC with
respect thereto.&#160; Each of the consolidated
balance sheets included in or incorporated by reference into the Teva Reports
(including the related notes and schedules) presents fairly, in all material
respects, the financial position of the Teva and its Subsidiaries as of its
date, and each of the consolidated statements of income and of consolidated
statements of cash flows included in or incorporated by reference into the Teva
Reports (including any related notes and schedules) fairly presents in all
material respects the results of operations, retained earnings and changes in financial
position, as the case may be, of the Teva and its Subsidiaries for the periods
set forth therein (subject, in the case of unaudited statements, to the absence
of notes and normal year-end audit adjustments), in each case in accordance
with U.S. GAAP consistently applied during the periods involved, except as may
be noted therein.&#160; Any change by Teva in
the accounting principles, practices or methods used in such financial
statements of Teva and its Subsidiaries included in the Teva Reports has been appropriately
disclosed in such financial statements.&#160;
Teva&#146;s disclosure controls and procedures (as defined in sections
13a-15(e) and 15d-15(e) of the Exchange Act) effectively enable Teva to comply
with, and the appropriate officers of Teva to make all certifications required
under, the Sarbanes-Oxley Act.&#160; Teva
qualifies as a &#147;foreign private issuer&#148; as defined in Rule 3b-4 under the
Exchange Act.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Disclosure
Documents</u>.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>None of the
information provided by Teva for inclusion in the Proxy Statement/Prospectus or
any amendment or supplement thereto, at the time the Proxy Statement/Prospectus
or any amendment or supplement thereto is first mailed to stockholders of Sicor
and at the time the stockholders vote on adoption of this Agreement, will contain
any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements make therein, in the light of the
circumstances under which they were made, not misleading.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Registration
Statements of Teva to be filed with the SEC with respect to the offering of
Teva ADSs representing Teva Ordinary Shares in connection with the Merger (the
&#147;<u>F-4 Registration Statement</u>&#148;) and the Teva ADSs issuable upon exercise
of the assumed Sicor Stock Options (such Registration Statement and the F-4
Registration Statement, collectively, the &#147;<u>Registration Statements</u>&#148;) and
any amendments or supplements thereto, when filed, will comply as to form in
all material respects with the requirements of the Securities Act.&#160; At the time a Registration Statement or any
amendment or supplement thereto becomes effective and at the Effective Time,
the Registration Statements, as amended or supplemented, will not contain any
untrue</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='25',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">statement of a material fact or omit to state any material fact
required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not
misleading.</font></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No
Undisclosed Material Liabilities</u>.&#160;
Except as set forth on Section&nbsp;5.2(g) of the Teva Disclosure
Schedules, there are no liabilities or obligations of Teva or any of its
Subsidiaries of any kind whatsoever in existence on the date hereof, whether
accrued, contingent, absolute, determined, determinable or otherwise,<b><font style="font-weight:bold;">  </font></b>other
than: (i) liabilities or obligations disclosed and provided for in the Teva
balance sheet as of June&nbsp;30, 2003 included in the Teva Reports or in the
notes thereto (the &#147;<u>Teva Balance Sheet</u>&#148;) or in the Teva Reports to the
date hereof; (ii) liabilities or obligations incurred in the ordinary course of
business consistent with past practices since June&nbsp;30, 2003; (iii)
liabilities and obligations not required to be disclosed on the Teva Balance
Sheet under U.S. GAAP and (iii) liabilities or obligations that would not
reasonably be expected have individually or in the aggregate, a Teva Material
Adverse Effect.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Absence
of Certain Changes</u>.&#160; Except as
described in the Teva Reports or as set forth on Schedule&nbsp;5.2(h) of the
Teva Disclosure Schedules, since the Audit Date, except as expressly
contemplated by this Agreement, Teva and its Subsidiaries taken as a whole have
conducted their business only in, and have not engaged in any material
transaction other than according to, the ordinary and usual course of such
business and there has not been (i) any change in the financial condition,
properties, assets, business or results of operations of Teva and its
Subsidiaries that has had or would be reasonably likely to have a Teva Material
Adverse Effect; (ii) any declaration, setting aside or payment of any dividend
or other distribution in respect of the capital stock of Teva or any
repurchase, redemption or other acquisition by Teva or any Subsidiary of any
securities of Teva other than regular quarterly dividends on shares of Teva
Common Stock in the ordinary course (including, in the case of Teva Ordinary
Shares, any periodic increase thereon consistent with past practice) or (iii)
any change by Teva in accounting principles, practices or methods which is not
required or permitted by U.S. GAAP.&#160;
Since the Audit Date and through the date hereof, except as provided for
herein, there has not been any material increase in the compensation payable or
that could become payable by Teva or any of its Significant Subsidiaries to
officers or key employees or any material amendment of any of the Compensation
and Benefit Plans other than increases or amendments in the ordinary course of
business consistent with past practice.&#160;
Except as disclosed in the Teva Reports, since January&nbsp;1, 2003,
there have not been any changes, circumstances or events which, individually or
in the aggregate, have had, or would reasonably be expected to have, a Teva
Material Adverse Effect.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Litigation</u>.&#160; Except as described in the Teva Reports or
as set forth on Schedule&nbsp;5.2(i) of the Teva Disclosure Schedules, there
are no civil, criminal or administrative actions, suits, claims, hearings,
investigations, reviews or proceedings pending or, to the knowledge of Teva
threatened against Teva or any of its Subsidiaries, except for those that would
not be reasonably likely to have, either individually or in the aggregate, a
Teva Material Adverse Effect.&#160; There are
no material SEC inquiries or investigations, other material governmental
inquiries or investigations or material internal investigations pending, or to
the knowledge of Teva, threatened, in each case regarding any accounting
practices of Teva or any of its Subsidiaries or any malfeasance by any director
or executive officer of Teva or any of its Subsidiaries.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='26',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Employee
Benefits</u>.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Teva has made
available to Sicor prior to the date hereof a copy of all Compensation and
Benefit Plans of Teva and its Significant Subsidiaries other than those that,
in the aggregate, are not material to Teva and its Subsidiaries, taken as a
whole (the &#147;<u>Teva Compensation and Benefit Plans</u>&#148;), and a copy of each
material agreement, policy, practice or arrangement that covers key employees
of Teva and its Significant Subsidiaries as a group.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All Teva Compensation
and Benefit Plans, to the extent subject to the ERISA and the Code are in
compliance in all material respects with the applicable provisions of ERISA,
the Code and other applicable Law.&#160; Each
Teva Pension Plan which is intended to be qualified under Section&nbsp;401(a)
of the Code has received a favorable determination letter from the IRS, and
nothing has occurred, whether by action or failure to act, that would cause the
loss of such qualification or that would result in costs to Teva or any of its
Significant Subsidiaries under the Internal Revenue Service&#146;s Employee Plans
Compliance Resolution System.&#160; There is
no material pending or, to the knowledge of Teva, threatened litigation or
other proceeding relating to Teva Compensation and Benefit Plans.&#160; Neither Teva nor any of its Significant
Subsidiaries has engaged in a transaction with respect to any Pension Plan
that, assuming the taxable period of such transaction expired as of the date
hereof, would subject Teva or any of its Significant Subsidiaries to a material
tax or penalty imposed by either Section&nbsp;4975 of the Code or
Section&nbsp;502(i) of ERISA.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>No liability under
Subtitle C or D of Title IV of ERISA has been or is expected to be incurred by
Teva or any of its Significant Subsidiaries with respect to any ongoing, frozen
or terminated &#147;single-employer plan,&#148; within the meaning of
Section&nbsp;4001(a)(15) of ERISA, currently or formerly maintained by any of
them, or the single-employer plan of any ERISA Affiliate.&#160; Teva and its Significant Subsidiaries have
not incurred and do not expect to incur any withdrawal liability with respect
to a multi-employer plan under Subtitle E of Title IV of ERISA (regardless of
whether based on contributions of an ERISA Affiliate).&#160; No notice of a &#147;reportable event,&#148; within
the meaning of Section&nbsp;4043 of ERISA for which the thirty (30) day
reporting requirement has not been waived or extended, other than an extension
pursuant to Pension Benefit Guaranty Corporation Reg. Section&nbsp;4043.66, has
been required to be filed for any Teva Pension Plan or by any ERISA Affiliate
within the twelve (12) month period ending on the date hereof.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All contributions
required to be made under the terms of any Teva Compensation and Benefit Plan
subject to United States law have been timely made or have been reflected on
the most recent consolidated balance sheet filed or incorporated by reference
in Teva Reports.&#160; Neither any Teva
Pension Plan nor any single-employer plan of an ERISA Affiliate has an
&#147;accumulated funding deficiency&#148; (whether or not waived) within the meaning of
Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA and no ERISA
Affiliate has an outstanding funding waiver.&#160;
Neither Teva nor any of its Significant Subsidiaries has provided, or is
required to provide, security to any Pension</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='27',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Plan subject to United States law or to any single-employer plan of an
ERISA Affiliate pursuant to Section&nbsp;401(a)(29) of the Code.</font></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Neither Teva nor its
Significant Subsidiaries have any material obligations for, or liabilities with
respect to, retiree health and life benefits under any Teva Compensation and
Benefit Plan subject to United States law, except for benefits required to be
provided under Section&nbsp;4980B of the Code or any other applicable law
requiring continuation of health coverage.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Notwithstanding anything
to the contrary contained in this Section&nbsp;5.2(j), the representations and
warranties contained in this Section&nbsp;5.2(j) shall be deemed to be true and
correct unless such failures to be true and correct are reasonably likely to
have a Teva Material Adverse Effect.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Neither the negotiation and
execution of this Agreement nor the consummation of the transactions
contemplated hereby will (either alone or upon the occurrence of any additional
or subsequent events) constitute an event under any Teva Compensation and
Benefit Plan that will or may result in any payment (whether of severance pay or
otherwise), acceleration of payment, forgiveness of indebtedness, vesting,
distribution, increase in benefits or obligation to fund benefits with respect
to any employee or former employee of Teva or any of its Significant
Subsidiaries.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(viii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>With respect to each Teva
Compensation and Benefit Plan not subject to United States law (a &#147;<u>Teva
Foreign Benefit Plan</u>&#148;):&#160; (i) each
Teva Foreign Benefit Plan is in material compliance with applicable Law; (ii)
each Teva Foreign Benefit Plan required to be registered with a regulatory
agency or authority has been registered and has been maintained in good
standing with such agency or authority, and (iii) as of the Effective Time, the
fair market value of the assets of each Teva Foreign Benefit Plan is sufficient
to provide for the accrued benefit obligations with respect to all current and
former participants in such plan according to the actuarial assumptions and
valuations most recently used to determine employer contributions to such Teva
Foreign Benefit Plan.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(k)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Compliance
with Laws</u>.&#160; The business of Teva and
its Subsidiaries is not being conducted in violation of any Laws, including FDA
and other Governmental Entity rules, regulations and policies relating to good
clinical practices, good manufacturing practices, good laboratory practices,
advertising and promotion, pre- and post-marketing adverse drug experience and
adverse drug reaction reporting, and all other pre- and post-marketing
reporting requirements, as applicable, except for violations that would not be reasonably
likely to have, either individually or in the aggregate, a Teva Material
Adverse Effect or prevent or materially impair the ability of Teva to
consummate the transactions contemplated by this Agreement.&#160; Teva is not debarred under the Generic Drug
Enforcement Act of 1992 and does not employ or use the services of any
individual who is debarred or, to the best of Teva&#146;s knowledge, has engaged in
any activity that could lead to debarment.&#160;
No investigation or review by any Governmental Entity with respect to
Teva or any of its Subsidiaries is pending or, to the knowledge of Teva,
threatened, nor has any Governmental Entity indicated in writing an</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='28',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">intention to conduct the same,
except for those the outcome of which would not be reasonably likely to have,
either individually or in the aggregate, a Teva Material Adverse Effect or
prevent or materially impair the ability of Teva to consummate the transactions
contemplated by this Agreement.&#160; Teva
and each of its Subsidiaries has all permits, licenses, franchises, variances,
exemptions, orders and other governmental authorizations, consents and
approvals from Governmental Entities necessary to conduct its business as
currently conducted, except for those the absence of which would not be
reasonably likely to have, either individually or in the aggregate, a Teva
Material Adverse Effect or prevent or materially impair the ability of Teva to
consummate the transactions contemplated by this Agreement.&#160; The provisions of this Section&nbsp;5.2(k)
shall not apply to Environmental Laws which are covered exclusively in Sections
5.2(l).</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(l)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Environmental
Matters</u>.&#160; Except as set forth on
Section&nbsp;5.2(l) of the Teva Disclosure Schedules and except for such
matters that would not, either individually or in the aggregate, be reasonably
likely to cause a Teva Material Adverse Effect:&#160; (i) the operations of Teva and its Subsidiaries are and have been
in compliance with all applicable Environmental Laws; (ii) each of Teva and each
of its Subsidiaries possesses and maintains in effect all environmental
permits, licenses, authorizations and approvals required under applicable
Environmental Laws with respect to the properties and business of Teva and its
Subsidiaries; (iii) neither Teva nor any of its Subsidiaries have received any
written environmental claim, notice or request for information concerning any
violation or alleged violation of any applicable Environmental Law, nor, to
Teva&#146;s knowledge, is there any existing factual or legal basis for any such
claim, notice or request for information; (iv) neither Teva nor any of its
Subsidiaries has any knowledge of a release or threat of release of any
Hazardous Substances which could reasonably be expected to result in liability
to Teva or any of it Subsidiaries at any of its or its Subsidiaries&#146; current or
former properties or at any other property arising from its or any of its
Subsidiaries&#146; current or former operations; (v) there are no writs,
injunctions, decrees, orders or judgments outstanding, or any actions, suits or
proceedings pending relating to compliance by Teva or any of its Subsidiaries
with any environmental permits, licenses, authorizations and approvals required
under applicable Environmental Laws or liability of Teva or any of its
Subsidiaries under any applicable Environmental Law; and (vi) no Lien has been
placed upon any of Teva&#146;s or its Subsidiaries&#146; properties (whether owned,
leased or managed) under any Environmental Law.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding any other provision of this Agreement to the contrary
(including, but not limited to, Section&nbsp;5.2(k)), the representations and
warranties of Teva in this Section&nbsp;5.2(m) constitute the sole
representations and warranties of Teva with respect to any Environmental Law or
Hazardous Substance.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(m)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Tax
Matters</u>.&#160; Teva and each of its
Subsidiaries (i) have duly and timely filed (taking into account any extension
of time within which to file) all material Tax Returns required to be filed by
any of them as of the date hereof and all such filed Tax Returns are complete
and accurate in all material respects; (ii) (A) have timely paid all Taxes that
are shown as due on such filed Tax Returns, except with respect to matters
contested in good faith and (B) no material penalties or charges are due with
respect to the late filing of any Tax Return required to be filed by or with
respect to any of them on or before the Effective Time; (iii) with respect to
all Tax material Returns filed by or with respect to any of them have not
waived any statute of</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='29',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">limitations with respect to
Taxes or agreed to any extension of time with respect to a Tax assessment or
deficiency; and (iv) as of the date hereof, does not have any deficiency, or
any such audits, examinations, investigations or other proceedings in respect
of Taxes or Tax matters pending or proposed or threatened in writing.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(n)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Labor
Matters</u>.&#160; Neither Teva nor any of
its Subsidiaries is the subject of any material proceeding asserting that Teva
or any of its Significant Subsidiaries has committed an unfair labor practice
or any other violation of law relating to employee matters, nor since
January&nbsp;1, 2003 has there been any labor strike, dispute, walk-out, work
stoppage, slow-down or lockout involving Teva or any of its Subsidiaries,
except for those that, either individually or in the aggregate, are not
reasonably likely to have a Teva Material Adverse Effect.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(o)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Intellectual
Property</u>.&#160; Except as described in
the Teva Reports or on Section&nbsp;5.2(o) of the Teva Disclosure Schedules,</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Teva or one of its
Subsidiaries owns, or is licensed or otherwise possesses sufficient legally
enforceable rights to use, all patents, trademarks, trade names, service marks,
copyrights, technology, know-how, computer software programs or applications,
databases and tangible or intangible proprietary information or materials that
are currently used in its and its Subsidiaries&#146; businesses (collectively, &#147;<u>Teva
Intellectual Property Rights</u>&#148;), except for any such failures to own, be
licensed or possess that, individually or in the aggregate, are not reasonably
likely to have a Teva Material Adverse Effect.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except for such
matters that, individually or in the aggregate, are not reasonably likely to
have a Teva Material Adverse Effect, (A) the use of Teva Intellectual Property
Rights by Teva or its Subsidiaries does not conflict with, infringe upon,
violate or interfere with or constitute an appropriation of any right, title,
interest or goodwill, including, without limitation, any intellectual property
right, patent, trademark, trade name, service mark, copyright of any other
Person and (B) there have been no claims made and neither Teva nor any of its
Subsidiaries has received written notice of any claim or otherwise knows that
any Teva Intellectual Property Right is invalid, or conflicts with the asserted
right of any other Person.</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(p)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Title
to Properties</u>.&#160; Teva and each of its
Subsidiaries has good and valid title to all of its material properties and
assets, free and clear of all Liens, except Liens for taxes not yet due and
payable and such Liens or other imperfections of title, if any, that,
individually or in the aggregate, are not reasonably likely to have a Teva
Material Adverse Effect.&#160; All leases
pursuant to which Teva and each of its Subsidiaries leases from others material
real or personal property are valid and effective in accordance with their
respective terms, and there is not, under any of such leases, any existing&#160; default or event of default of Teva or any
of its Subsidiaries or, to the knowledge of Teva, any other party (or any event
which with notice or lapse of time, or both, would constitute a material
default), that, individually or in the aggregate, are reasonably likely to have
a Teva Material Adverse Effect.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='30',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(q)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Contracts</u>.&#160; Neither Teva nor any of its Subsidiaries has
breached, or received in writing any claim or notice that it has breached, any
of the terms and conditions of any Contract to which it is a party or by which
it is bound in such a manner as, individually or in the aggregate, are
reasonably likely to have a Teva Material Adverse Effect.&#160; Each Contract to which Teva or any of its
Subsidiaries is a party or by which it is bound that has not expired or
terminated by its terms is in full force and effect, except where the failure
to be in full force and effect is not reasonably likely to have a Teva Material
Adverse Effect.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(r)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Product
Liability</u>.&#160; No product liability
claims have been asserted in writing against Teva or any of its Subsidiaries
or, to the knowledge of Teva, threatened against Teva or any of its
Subsidiaries relating to any or their products or product candidates developed,
tested, manufactured, marketed, distributed or sold by Teva or any of its
Subsidiaries, except for claims that, individually or in the aggregate, are not
reasonably likely to have a Teva Material Adverse Effect.&#160; There is no Order outstanding against Teva
or any of its Subsidiaries relating to product liability claims or assessments.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(s)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Insurance</u>.&#160; Teva maintains for itself and its
Subsidiaries insurance policies covering the assets, business, equipment,
properties, operations, employees, directors and officers, and product warranty
and liability claims, and such other forms of insurance in such amounts, with
such deductibles and against such risks and losses as, in its judgment, are
reasonable for the business and assets of Teva and its Subsidiaries.&#160; All such insurance policies are in full
force and effect, all premiums due and payable thereon have been paid, and Teva
and its Subsidiaries are otherwise in compliance with the terms and conditions
of such policies and bonds except for failures to so comply that, individually
or in the aggregate, are not reasonably likely to have a Teva Material Adverse
Effect.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(t)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No
Business Activities</u>.&#160; Merger Sub is
not a party to any material agreement and has not conducted any activities
other than in connection with the organization of Merger Sub, the negotiation and
execution of this Agreement and the consummation of the transactions
contemplated hereby.&#160; Merger Sub has no
Subsidiaries.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(u)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No
Vote Required</u>.&#160; No approval of the
stockholders of Teva is required to approve this Agreement and the transactions
contemplated hereby.&#160; The vote or
consent of Teva as the sole stockholder of Merger Sub (which shall have
occurred prior to the Effective Time) is the only vote or consent of the
holders of any class or series of capital stock of Merger Sub necessary to
approve this Agreement, the Merger or the transactions contemplated hereby.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Ownership
of Sicor Common Stock</u>.&#160; Except
pursuant to the Stockholders Agreement, neither Teva, Merger Sub nor any of
their respective Subsidiaries or, to the knowledge of Teva, any of their
respective affiliates or associates (as such terms are defined under the
Exchange Act) (i) beneficially owns, directly or indirectly, or (ii) is a party
to any agreement, arrangement or understanding for the purpose of acquiring,
holding, voting or disposing of, in case of either clause (i) or (ii), any
shares of Sicor Common Stock.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(w)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Transactions
with Affiliates</u>.&#160; Except as
disclosed on Section&nbsp;5.2(w) of the Teva Disclosure Schedules or in the
Teva Reports, no present or former affiliate of Teva has, or since</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='31',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;31, 2001 has had,
(i) any interest in any property (whether real, personal or mixed and whether
tangible or intangible) used in or pertaining to any of the businesses of Teva
or any of its Subsidiaries, (ii) has had business dealings or a material
financial interest in any transaction with Teva or any of its Subsidiaries
(other than compensation and benefits received in the ordinary course of
business as an employee or director of Teva or any of its Subsidiaries) or
(iii) any material equity interest or any other material financial or profit
interest in any Person that has had business dealings or a material financial
interest in any transaction with Teva or any of its Subsidiaries.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(x)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Brokers
and Finders</u>.&#160; Except for Credit
Suisse First Boston LLC and Lehman Brothers Inc., the fees, commissions and
expenses of which will be paid by Teva, neither Teva, Merger Sub nor any of
their respective officers, directors or employees has employed any broker or
finder or incurred any liability for any brokerage fees, commissions or
finders&#146; fees in connection with the Merger, this Agreement, the Stockholders
Agreement and the other transactions contemplated hereby and thereby.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(y)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Opinion
of Financial Advisor</u>.&#160; Teva has
received opinions of Credit Suisse First Boston LLC and Lehman Brothers Inc.,
dated as of the date hereof, to the effect that, as of such date, the Merger
Consideration to be paid to holders of Sicor Common Stock in the Merger is fair
from a financial point of view to Teva.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(z)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Financial
Capability</u>.&#160; Teva has the financial
capacity to perform and to cause Merger Sub to perform its obligations under
this Agreement, and Teva has currently available cash or cash equivalents that,
together with committed bank lines of credit, are sufficient to permit Teva to
fund the Cash Consideration set forth in Article&nbsp;III and any other amounts
payable by Teva or Merger Sub contemplated by this Agreement.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(aa)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No
Other Representations or Warranties</u>.&#160;
Except for the representations and warranties contained in this
Section&nbsp;5.2, neither Teva nor any other Person makes any other express or
implied representation or warranty on behalf of Teva or any of its Subsidiaries.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><a name="Articlevi"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;VI</font></a></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">CONDUCT OF BUSINESS PENDING THE MERGER</font></u></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="CovenantsofSicor28"><u>Covenants of Sicor</u></a>.&#160; Sicor covenants and agrees as to itself and
its Subsidiaries that, from the date hereof and continuing until the Effective
Time, except as expressly contemplated or permitted by this Agreement, as
required by Law or to the extent Teva shall otherwise consent in writing, which
decision regarding consent shall not be unreasonably withheld or delayed:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sicor
shall conduct its business only in the ordinary and usual course and, to the
extent consistent therewith, it and its Subsidiaries shall use their respective
commercially reasonable efforts to (i) subject to prudent management of
workforce needs and ongoing programs currently in force, preserve its business
organization intact and maintain its existing relations and goodwill with
customers, suppliers, distributors, creditors, lessors, employees and business
associates, (ii) maintain and keep material properties and assets in good
repair and</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='32',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">condition and (iii) maintain in
effect all material governmental permits pursuant to which such party or any of
its Significant Subsidiaries currently operates;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sicor
shall not (i) amend its certificate of incorporation or by-laws or the
comparable governing instruments of any of its Subsidiaries except for such
amendments that would not prevent or materially impair the consummation of the
transactions contemplated by this Agreement or by the Stockholders Agreement;
(ii) split, combine or reclassify its outstanding shares of capital stock;
(iii) declare, set aside or pay any dividend payable in cash, stock or property
in respect of any capital stock (other than dividends from its direct or
indirect wholly-owned Subsidiaries to it or a wholly-owned Subsidiary) or (iv) repurchase,
redeem or otherwise acquire any shares of its capital stock or any securities
convertible into or exchangeable or exercisable for any shares of its capital
stock or permit any of its Subsidiaries to purchase or otherwise acquire, any
shares of its capital stock or any securities convertible into or exchangeable
or exercisable for any shares of its capital stock (other than for the purpose
of funding or providing benefits under Sicor Stock Plans);</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>neither
Sicor nor any of its Subsidiaries shall issue, sell, pledge, dispose of or
encumber any shares of, or securities convertible into or exchangeable or
exercisable for, or options, warrants, calls, commitments or rights of any kind
to acquire, any shares of its capital stock of any class or any Voting Debt or
any other property or assets (other than shares of common stock issuable
pursuant to options or restricted share units (whether or not vested)
outstanding on the date hereof under the Sicor Stock Plans, issuances of
additional options or restricted share units or rights to acquire shares of
common stock granted pursuant to the terms of the Sicor Stock Plans as in
effect on the date hereof in the ordinary and usual course of the operation of
such stock plans and issuances of shares of common stock pursuant to options or
restricted share units granted after the date hereof pursuant to the Sicor
Stock Plans);</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>neither
Sicor nor any of its Subsidiaries shall, other than in the ordinary and usual
course of business and other than transactions not in excess of $10,000,000 in
the aggregate in any calendar year, transfer, lease, license, guarantee, sell,
mortgage, pledge, dispose of or encumber any other property or assets
(including capital stock of any of its Subsidiaries);</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>neither
Sicor nor any of its Subsidiaries shall, by any means, make any acquisition of,
or investment in, assets or stock (whether by way of merger, consolidation,
tender offer, share exchange or other activity) in any transaction or any
series of transactions (whether or not related) for an aggregate purchase price
or prices, including the assumption of any debt, in excess of $10,000,000 in
the aggregate in any calendar year, except for acquisitions mandated by binding
legal commitments existing on the date hereof or necessary to meet obligations
to serve;</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>except
as disclosed in Schedule&nbsp;6.1(f) of the Sicor Disclosure Schedules, neither
Sicor nor any of its Subsidiaries shall, other than in the ordinary and usual
course of business, (i) modify, amend, or terminate any Contract that is
material to Sicor and its Subsidiaries taken as a whole, (ii) waive, release,
relinquish or assign any such Contract (or any of the material rights of Sicor,
or any of its Subsidiaries thereunder), right or claim, or (iii) cancel or forgive
any material indebtedness owed to Sicor or any of its Subsidiaries;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='33',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sicor
will not (i) adopt a plan of complete or partial liquidation, dissolution,
merger, consolidation, recapitalization or other similar reorganization of such
party or any Significant Subsidiary of such party, or (ii) accelerate or delay
collection of notes or accounts receivable in advance of or beyond their
regular due dates, other than in the usual and ordinary course of business;</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>neither
Sicor nor any of its Subsidiaries shall terminate, establish, adopt, enter
into, make any new grants or awards under, amend or otherwise modify any
Compensation and Benefit Plans (other than issuances of additional shares of
common stock or options or rights to acquire shares of common stock, granted
pursuant to the terms of such party&#146;s stock plans as in effect on the date
hereof in the ordinary and usual course of the operation of such stock plans),
or increase the salary, wage, bonus or other compensation of any employees
except for (i) grants or awards or increases occurring in the ordinary and
usual course of business (which shall include normal periodic performance
reviews and related compensation and benefit increases), (ii) annual reestablishment
of Compensation and Benefit Plans and the provision of individual compensation
or benefit plans and agreements for newly hired or appointed officers and
employees of such party and its Subsidiaries or (iii) actions necessary to
satisfy existing contractual obligations under Compensation and Benefit Plans
or agreements existing as of the date hereof;</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sicor
shall, and shall cause its Subsidiaries to, maintain with financially
responsible insurance companies (or through self insurance) insurance in such
amounts and against such risks and losses as are consistent with the insurance
maintained by such party and its Subsidiaries in the ordinary course of
business consistent with past practice;</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>except
in the ordinary and usual course of business or as may be required by
applicable Law and except to the extent required by U.S. GAAP as advised by
such party&#146;s regular independent accountants, neither Sicor nor any of its
Subsidiaries shall change any accounting principle, practice or method in a
manner that is inconsistent with past practice;</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(k)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sicor
shall not, and shall not permit any of its Subsidiaries to, take any action
that could reasonably be expected to result in (a) any representation or
warranty of such party set forth in this Agreement that are qualified by
materiality becoming untrue, (b) any such representations and warranties that
are not so qualified becoming untrue in any material respect, (c) any of the
conditions to the Merger set forth in Article&nbsp;VIII not being satisfied or
(d) otherwise prevent or materially impair or delay the ability of such party
to consummate the transactions contemplated by this Agreement;</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(l)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sicor
and each of its Subsidiaries shall (i) file all material Tax Returns required
to be filed with any taxing authority in accordance with all applicable laws,
(ii) timely pay all taxes due and payable as shown in the respective Tax
Returns that are so filed and, as of the time of filing, the Tax Returns will
be based on tax positions that have substantial support, and (iii) promptly
notify Teva of any action, suit, proceeding, investigation, audit or claim
initiated or pending against or with respect to Sicor or any of its
Subsidiaries in respect of any Tax where there is a reasonable possibility of a
determination or decision that would reasonably be expected</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='34',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">to have a Material Adverse
Effect on the Tax liabilities or other Tax attributes of Sicor or its
Subsidiaries;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(m)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>neither
Sicor nor any of its Subsidiaries shall make any Tax election or settle or
compromise any income tax liability without the prior written consent of Teva,
which shall not be unreasonably withheld;</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(n)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sicor
shall not redeem the Rights outstanding under the Stockholders Rights Plan, or
amend, modify or terminate the Stockholders Rights Plan or render it
inapplicable to (or otherwise exempt from the application of the Stockholders
Rights Plan) any Person or action, other than to render the Rights inapplicable
to the execution, delivery and performance of this Agreement, the Stockholders
Agreement and the Merger; <u>provided</u> that the foregoing shall not apply to
any such actions that are taken in connection with entering into an Acquisition
Proposal to the extent permitted by Section&nbsp;7.2;</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(o)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>neither
Sicor nor any of its Subsidiaries will enter into any Contract that purports to
limit or prohibit in any respect Sicor or any of its Subsidiaries (A) from
competing with any other Person, (B) from acquiring any product or other asset
or any services from any other Person, (C) from developing, selling, supplying,
distributing, offering, supporting or servicing any product or any technology
or other asset to or for any other Person or (D) from transacting business or
dealing in any other manner with any other Person, except such a Contract (i)
entered into in the ordinary course of business, (ii) that is able to be
terminated by Sicor or its Subsidiaries without penalty, or otherwise expires
on its terms, within two years of the date thereof, and (iii) that does not
bind any Affiliates of Sicor (other than its Subsidiaries); and</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(p)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>neither
Sicor nor any of its Subsidiaries will authorize or enter into an agreement to
do anything prohibited by the foregoing.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="CovenantsofTeva29"><u>Covenants of Teva</u></a>.&#160; Teva covenants and agrees as to itself and its Subsidiaries (as
applicable) that, from the date hereof and continuing until the Effective Time,
except as expressly contemplated or permitted by this Agreement, except as
described in Schedule&nbsp;6.2 of the Teva Disclosure Schedules, as required by
Law or to the extent Sicor shall otherwise consent in writing, which decision
regarding consent shall be made as soon as reasonably practicable:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Teva
shall conduct its business only in the ordinary and usual course and, to the extent
consistent therewith, it and its Subsidiaries shall use their respective
commercially reasonable efforts to (i) subject to prudent management of
workforce needs and ongoing programs currently in force, preserve its business
organization intact and maintain its existing relations and goodwill with
customers, suppliers, distributors, creditors, lessors, employees and business
associates, (ii) maintain and keep material properties and assets in good
repair and condition and (iii) maintain in effect all material governmental
permits pursuant to which such party or any of its Significant Subsidiaries
currently operates;</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Teva
shall not (i) amend its Memorandum or Articles of Association or the comparable
governing instruments of any of its Subsidiaries except for such amendments
that would not prevent or materially impair the consummation of the
transactions contemplated by this Agreement; (ii) split, combine or reclassify
its outstanding shares of capital stock without</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">35</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='35',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">adjusting the Merger
Consideration pursuant to Section&nbsp;3.4; (iii) declare, set aside or pay any
dividend payable in cash, stock or property in respect of any capital stock
(other than dividends from its direct or indirect wholly-owned Subsidiaries to
it or a wholly-owned Subsidiary and other than the declaration and payment of
regular quarterly dividends consistent with past practice) or (iv) repurchase,
redeem or otherwise acquire any shares of its capital stock or any securities
convertible into or exchangeable or exercisable for any shares of its capital
stock or permit any of its Subsidiaries to purchase or otherwise acquire, any
shares of its capital stock or any securities convertible into or exchangeable
or exercisable for any shares of its capital stock (other than for the purpose
of funding or providing benefits under the Teva Stock Plans);</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Teva
will not adopt a plan of complete or partial liquidation, dissolution, merger,
consolidation, recapitalization or other similar reorganization of such party
or any of its Significant Subsidiaries;</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Teva
shall not, nor shall it permit any of its Subsidiaries to, take any action that
could reasonably be expected to result in (a) any representation or warranty of
such party set forth in this Agreement that are qualified by materiality
becoming untrue, (b) any such representations and warranties that are not so
qualified becoming untrue in any material respect, (c) any of the conditions to
the Merger set forth in Article&nbsp;VIII not being satisfied or (d) otherwise
prevent or materially impair or delay the ability of such party to consummate
the transactions contemplated by this Agreement; and</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Neither
Teva nor any of its Subsidiaries will authorize or enter into an agreement to
do anything prohibited by the foregoing.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="NoControlofOtherPartysBusiness30"><u>No Control of Other Party&#146;s Business</u></a>.&#160; Nothing contained in this Agreement shall
give Teva, directly or indirectly, the right to control or direct Sicor&#146;s or
its Subsidiaries&#146; operations prior to the Effective Time, and nothing contained
in this Agreement shall give Sicor, directly or indirectly, the right to
control or direct Teva&#146;s or its Subsidiaries&#146; operations prior to the Effective
Time.&#160; Prior to the Effective Time, each
of Sicor and Teva shall exercise, consistent with the terms and conditions of
this Agreement, complete control and supervision over its and its Subsidiaries&#146;
respective operations.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><a name="Articlevii"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;VII</font></a></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">ADDITIONAL AGREEMENTS</font></u></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="Access33"><u>Access</u></a>.&#160; Teva
and Sicor agree that upon reasonable notice, and except as may otherwise be
required or restricted by applicable Law, each shall (and shall cause its
Subsidiaries to) afford the other&#146;s officers, employees, counsel, accountants
and other authorized representatives (&#147;<u>Representatives</u>&#148;) reasonable
access, during normal business hours throughout the period prior to the
Effective Time, to its executive officers, to its properties, books, contracts
and records and, during such period, each shall (and each shall cause its
Subsidiaries to) furnish promptly to the other all information concerning its
business, properties and personnel as may reasonably be requested but only to
the extent such access does not unreasonably interfere with the business or
operations of such party; <i><font style="font-style:italic;">provided</font></i> that no investigation pursuant to
this Section</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='36',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shall affect or be deemed to
modify any representation or warranty made by Sicor, Teva or Merger Sub in this
Agreement.&#160; All requests for information
made pursuant to this Section&nbsp;7.1 shall be directed to an executive
officer of Teva or Sicor, as applicable, or its financial advisors or such
other Person as may be designated by either of its executive officers.&#160; All such information shall be governed by
the terms of the Confidentiality Agreement.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="AcquisitionProposals34"><u>Acquisition Proposals</u></a>.&#160; Sicor shall not, nor shall it permit or
authorize any of its Subsidiaries or any officer, director, employee, agent or
representative (including accountants, attorneys and investment bankers) of
Sicor or any of its Subsidiaries to, directly or indirectly, initiate, solicit,
encourage or otherwise facilitate (including by way of furnishing confidential
information) any inquiries or the making of any proposal or offer, with respect
to (i) any merger, reorganization, share exchange, business combination,
recapitalization, consolidation, liquidation, dissolution or similar
transaction involving Sicor or its Significant Subsidiaries, (ii) any sale,
lease, exchange, mortgage, pledge, transfer or purchase of the assets or equity
securities of Sicor or any of its Subsidiaries, in each case comprising 15% or
more in value of Sicor and its Subsidiaries, taken as a whole, in a single
transaction or series of related transactions or (iii) any purchase or sale of,
or tender offer or exchange offer for, fifteen percent (15%) or more of the
outstanding shares of Sicor Common Stock (any such proposal or offer (other
than a proposal or offer by Teva) being hereinafter referred to as an &#147;<u>Acquisition
Proposal</u>&#148;).&#160; Sicor shall not, nor
shall it permit or authorize any of its Subsidiaries or any officer, director,
employee, agent or representative (including accountants, attorneys and
investment bankers) of Sicor or any of its Subsidiaries to, directly or
indirectly, (a) engage in any negotiations concerning, or provide any
confidential information or data to, or have any discussions (other than
discussions that only refer to this Section&nbsp;and Sicor&#146;s agreement not to
engage in further discussions) with, any Person relating to an Acquisition
Proposal, or otherwise facilitate any effort or attempt to make or implement or
accept an Acquisition Proposal, (b) withdraw or modify, or propose to withdraw
or modify, its approval or recommendation of this Agreement or the transactions
contemplated hereby, including the Merger, (c) approve, recommend, endorse or
resolve to approve, recommend or endorse an Acquisition Proposal or (d) enter
into any letter of intent or similar document contemplating, or enter into any
agreement (other than a confidentiality agreement entered into in accordance
with clause (A) below or a joint defense agreement with a party that has
entered into such a confidentiality agreement) with respect to, an Acquisition
Proposal; <i><font style="font-style:italic;">provided,
however</font></i>, that nothing contained in this Agreement shall prevent the
Board of Directors of Sicor or its representatives (including accountants,
attorneys and investment bankers) from (A) furnishing information to a third
party in response to an unsolicited bona fide written Acquisition Proposal by
such third party pursuant to a confidentiality agreement which may include
changes necessary in order to allow Sicor to be able to comply with this
Agreement but with terms and conditions similar to the Confidentiality
Agreement (provided that such confidentiality agreement may not include any
provision granting any such Person or group an exclusive right to negotiate
with Sicor), concerning Sicor and its business, properties or assets, (B)
engaging in discussions or negotiations with such third party, (C) following
receipt of a bona fide unsolicited written Acquisition Proposal, taking and
disclosing to its stockholders a position contemplated by Rule 14e-2(a) under
the Exchange Act, (D) following receipt of a bona fide unsolicited written
Acquisition Proposal, recommending such an Acquisition Proposal to its
stockholders or adopting an agreement relating to such Acquisition Proposal,
(E) following receipt of a bona fide unsolicited written Acquisition</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='37',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proposal, failing to make or
withdrawing or modifying its recommendation or declaration of advisability of
the Merger or adoption of this Agreement, (F) taking any non-appealable, final
action ordered to be taken by Sicor by any court of competent jurisdiction
and/or (G) making any disclosure or filing, in its reasonable judgment after
receiving advice from outside counsel, that is required by Law (including,
without limitation, the DGCL and the rules and regulations promulgated under
the federal securities laws), stock exchange rules or the rules, regulations,
order or request of any Governmental Entity (including the SEC), but in each
case referred to in the foregoing clauses (A) through (E) only if (i) the Sicor
Requisite Vote has not been obtained, (ii) if such third party has submitted a
Superior Proposal which is pending at the time Sicor determines to take such
action or, in the cases of action pursuant to clauses (A) and (B), the Board of
Directors of Sicor shall have concluded in good faith that such bona fide
Acquisition Proposal would reasonably be expected to constitute or result in a
Superior Proposal, and (iii) the Sicor Board of Directors determines in good
faith, after consultation with outside counsel, that a failure to take such
action would be inconsistent with the discharge of the Sicor Board of
Director&#146;s fiduciary duties to the Sicor stockholders under Delaware Law; <i><font style="font-style:italic;">provided,
further</font></i>, that the Board of Directors of Sicor shall not take any of
the foregoing actions referred to in clauses (D) and (E) above, until at least
three (3) calendar days shall have passed following Teva&#146;s receipt of written
notice from Sicor advising Teva that the Sicor Board of Directors has received
such a Superior Proposal which it intends to accept, specifying the material
terms and conditions of such Superior Proposal, and Teva does not make an offer
that the Sicor Board of Directors shall have concluded in its good faith
judgment, after consultation with its financial advisors and outside counsel,
is as favorable (taking into account the termination fee payable hereunder) to
Sicor&#146;s stockholders as such Superior Proposal.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sicor will promptly (and in any event within one business day) notify
Teva in writing, of the existence of any material proposal, material
discussion, material negotiation or material inquiry received by Sicor with
respect to any Acquisition Proposal, and Sicor will immediately communicate to
Teva the material terms of any proposal, discussion, negotiation or inquiry
which it may receive and the identity of the Person making such proposal or
inquiry or engaging in such discussion or negotiation.&#160; Sicor will promptly provide to Teva any
non-public material information concerning Sicor provided to any other Person
that was not previously provided to Teva on the same day as the providing of
any such information to any other Person.&#160;
Sicor will keep Teva reasonably informed of the status and details of
any such Acquisition Proposal (including modifications or proposed
modifications thereto).</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Without prejudice to any actions permitted to be taken by Sicor
pursuant to the immediately preceding paragraph, Sicor agrees that it will, and
will cause its officers, directors and representatives to, immediately cease
and cause to be terminated any existing activities, discussions or negotiations
with any parties conducted heretofore with respect to any Acquisition
Proposal.&#160; In addition, Sicor shall
promptly request that each Person who has heretofore executed a confidentiality
agreement in connection with such Person&#146;s consideration of an Acquisition
Proposal return or destroy all confidential information heretofore furnished to
such Person by or on behalf of Sicor in accordance with such confidentiality
agreement.&#160; Sicor shall not release any
third party from, or waive any provision of, any such confidentiality agreement
or any other confidentiality or standstill agreement to which Sicor is a
party.&#160; Sicor agrees that it will take
the</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='38',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">necessary steps to promptly
inform the individuals or entities referred to in the first sentence hereof of
the obligations undertaken by Sicor in this Section&nbsp;7.2.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Nothing in this Section&nbsp;7.2 shall (x) permit Sicor to terminate
this Agreement (except as specifically provided in Article&nbsp;IX hereof) or
(y) affect any other obligation of Sicor under this Agreement.&#160; Notwithstanding anything to the contrary
contained in this Section&nbsp;7.2 or elsewhere in this Agreement, prior to the
Effective Time, Sicor may, in connection with a possible Acquisition Proposal,
refer any third party to this Section&nbsp;7.2 and Section&nbsp;9.5(b) and make
a copy of this Section&nbsp;7.2 and Section&nbsp;9.5(b) available to a third
party.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Superior Proposal</u>&#148; means an Acquisition Proposal to acquire,
directly or indirectly, for consideration consisting solely of cash and/or
marketable securities, 30% or more of the Sicor Common Stock then outstanding
or 40% or more of the assets of Sicor and its Subsidiaries, taken as a whole,
in a single transaction or a series of related transactions, and otherwise on
terms which the Sicor Board of Directors determines in good faith (after
consultation with its outside legal counsel and financial advisor), taking into
account, among other things, all legal, financial, regulatory and other aspects
of the proposal and the third party making the proposal, (i) to be more
favorable to the Company&#146;s stockholders than the Merger (after considering the
views of the Company&#146;s independent financial advisor with respect to the value
of the consideration provided for in such proposal as it compares to the value
of the consideration provided for in the Merger) and (ii) which, in the good
faith reasonable judgment of the Sicor Board of Directors, is reasonably
capable of being consummated without undue delay.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="SicorStockholdersMeeting35"><u>Sicor Stockholders Meeting</u></a>.&#160; Subject to the fiduciary duties of Sicor&#146;s
Board of Directors under applicable Law and its rights and obligations under
Section&nbsp;7.2, in each case as determined by the Board of Directors of
Sicor, Sicor will take, in accordance with applicable Law and its certificate
of incorporation, as amended, and by-laws, all action necessary to convene a
meeting of holders of shares of Sicor Common Stock as promptly as practicable
after the Proxy Statement/Prospectus is mailed to its stockholders to consider
and vote upon the approval of this Agreement and the transactions contemplated
hereby.&#160; Subject to fiduciary
obligations under applicable Law and its rights and obligations under
Section&nbsp;7.2 in each case as determined by the Board of Directors of Sicor
in accordance with this Agreement, Sicor&#146;s Board of Directors shall recommend
such approval and take all lawful action to solicit such approval.&#160; Notwithstanding any change or withdrawal of
Sicor&#146;s recommendation&#160; or declaration
of advisability of the Merger and adoption of this Agreement pursuant to
Section&nbsp;7.2, this Agreement shall be submitted to the Sicor stockholders
at a meeting of holders of shares of Sicor Common Stock in accordance with this
Section&nbsp;7.3 to consider and vote upon the approval of this Agreement and
the transactions contemplated hereby.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="FilingsOtherActionsNotification36"><u>Filings; Other Actions; Notification</u></a>.&#160; (a)&#160;
Each party hereto shall file or cause to be filed with (i) the Federal
Trade Commission and the Department of Justice any notifications required to be
filed under the HSR Act and (ii) the appropriate Governmental Entity each of
the Foreign Antitrust Filings, in each case in accordance with the applicable
rules and regulations promulgated under the relevant Law, with respect to the
transactions contemplated hereby and by the Stockholders Agreement.&#160; Each party hereto will use all commercially
reasonable efforts to</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='39',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">make such filings in a timely
manner and to respond on a timely basis to any requests for additional
information made by any such agency.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sicor
and Teva shall cooperate with each other and use (and shall cause their
respective Subsidiaries to use) all commercially reasonable efforts to take or
cause to be taken all actions, and do or cause to be done all things,
necessary, proper or advisable on its part under this Agreement and applicable
Laws to consummate and make effective the Merger and the other transactions
contemplated hereby and by the Stockholders Agreement as soon as practicable,
including preparing and filing as soon as practicable all documentation to
effect all necessary notices, reports and other filings and to obtain as soon
as practicable all Sicor Required Statutory Approvals or Teva Required
Statutory Approvals, as the case may be, and all consents, registrations,
approvals, permits and authorizations necessary or advisable to be obtained
from any third party in order to consummate the Merger or any of the other
transactions contemplated hereby and by the Stockholders Agreement.&#160; Subject to applicable Laws relating to the
exchange of information and the preservation of any applicable attorney-client
privilege, work-product doctrine, self-audit privilege or other similar
privilege, Teva and Sicor shall have the right to review and comment on in
advance, and to the extent practicable each will consult the other on, all the
information relating to Teva or Sicor, as the case may be, and any of their
respective Subsidiaries, that appear in any filing made with, or written materials
submitted to, any third party and/or any Governmental Entity in connection with
the Merger and the other transactions contemplated hereby and by the
Stockholders Agreement.&#160; In exercising
the foregoing right, each of Sicor and Teva shall act reasonably and as
promptly as practicable.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject
to applicable Laws and the preservation of any applicable attorney-client
privilege, Sicor and Teva each shall, upon request by the other, furnish the
other with all information concerning itself, its Subsidiaries, directors,
officers and stockholders and such other matters as may be reasonably necessary
or advisable in connection with the Proxy Statement/Prospectus or any other
statement, filing, notice or application made by or on behalf of Teva, Sicor or
any of their respective Subsidiaries to any third party and/or any Governmental
Entity in connection with the Merger and the other transactions contemplated
hereby and by the Stockholders Agreement.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject
to any confidentiality obligations and the preservation of any attorney-client
privilege, Sicor and Teva each shall keep the other apprised of the status of
matters relating to completion of the transactions contemplated hereby and by
the Stockholders Agreement, including promptly furnishing the other with copies
of notices or other communications received by Teva or Sicor, as the case may
be, or any of its Subsidiaries, from any third party and/or any Governmental
Entity with respect to the Merger and the other transactions contemplated
hereby and by the Stockholders Agreement.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject
to the fiduciary duties of Sicor&#146;s Board of Directors under the DGCL and its
rights and obligations under Section&nbsp;7.2, in each case as determined by
the Board of Directors of Sicor, in the event that any administrative or
judicial action or proceeding is instituted (or threatened to be instituted) by
a Governmental Entity or private party challenging any transaction contemplated
by this Agreement, or any other agreement contemplated hereby each of Teva,
Merger Sub and Sicor shall cooperate in all respects with each other and use
all of their</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='40',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">respective commercially
reasonable efforts to contest and resist any such action or proceeding and to
have vacated, lifted, reversed or overturned any decree, judgment, injunction
or other order, whether temporary, preliminary or permanent, that is in effect
and that prohibits, prevents or restricts consummation of the transactions
contemplated by this Agreement.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In
furtherance and not in limitation of the covenants of the parties contained in
paragraph (a)-(e) of this Section&nbsp;7.4, if any objections are asserted with
respect to the transactions contemplated hereby under any Antitrust Law or if
any suit is instituted (or threatened to be instituted) by the Federal Trade
Commission, the Department of Justice or any other applicable Governmental
Entity challenging any of the transactions contemplated hereby as violative of
any Antitrust Law (as defined below) or which would otherwise prohibit or
materially impair or materially delay the consummation of the transactions
contemplated hereby, each of Teva, Merger Sub and Sicor shall use its
reasonable best efforts to resolve any such objections or suits so as to permit
consummation of the transactions contemplated by this Agreement, including,
without limitation, selling, holding separate or otherwise disposing of or
conducting its business in a manner which would resolve such objections or
suits or agreeing to sell, hold separate or otherwise dispose of or conduct its
business in a manner which would resolve such objections or suits or permitting
the sale, holding separate or other disposition of, any of its assets or the
assets of its Subsidiaries or the conducting of its business in a manner which
would resolve such objections or suits; provided, that, in no event shall any
of Teva, Merger Sub and Sicor be required to take any action, that,
individually or together with any other such actions, would reasonably be
expected to have either a Sicor Material Adverse Effect or a Teva Material
Adverse Effect (each defined, for purposes of this Section&nbsp;7.4(f) to
include prospects of Teva and its Subsidiaries or Sicor and its Subsidiaries,
as applicable).&#160; Without excluding other
possibilities, the transactions contemplated by this Agreement shall be deemed
to be materially delayed if unresolved objections or suits delay or could
reasonably be expected to delay the consummation of the transactions
contemplated hereby beyond the period, including any extension as therein
provided, contemplated by Section&nbsp;9.2(a) of this Agreement.&#160; &#147;<u>Antitrust Law</u>&#148; means the Sherman
Act, as amended, the Clayton Act, as amended, the HSR Act, the Federal Trade
Commission Act, as amended, and all other federal, state and foreign, if any,
Laws that are designed or intended to prohibit, restrict or regulate actions
having the purpose or effect of monopolization or restraint of trade or
lessening of competition through merger or acquisition.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="ProxyStatementProspectusF4Registra37"><u>Proxy Statement/Prospectus; F-4
Registra</u></a><u>tion Statement</u>.&#160;
(a)&#160; As promptly as practicable
after the execution and delivery of this Agreement, Teva and Sicor shall
prepare and file with the SEC the Proxy Statement/Prospectus, and Teva shall
prepare and file with the SEC the F-4 Registration Statement (in which the
Proxy Statement/Prospectus shall be included) covering the Teva ADSs to be
issued in the Merger.&#160; Each of Teva and
Sicor shall use all commercially reasonable efforts to cause such F-4
Registration Statement to become effective under the Securities Act as soon
practicable after the date of such filing and to keep the F-4 Registration
Statement effective as long as is necessary to consummate the Merger.&#160; The Proxy Statement/Prospectus shall include
the recommendation of the Board of Directors of Sicor in favor of approval and
adoption of this Agreement and the Merger, except to the extent the Board of
Directors of Sicor shall have withdrawn or modified its approval or
recommendation as permitted by Section&nbsp;7.2.&#160; Each of Teva and Sicor shall use all commercially reasonable
efforts to cause the Proxy Statement/Prospectus to be mailed to the holders of
Sicor Common Stock as</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='41',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">promptly as practicable after
the F-4 Registration Statement becomes effective.&#160; Teva and Sicor shall promptly provide to each other (i) notice of
any oral comments to the Proxy Statement/Prospectus or the F-4 Registration
Statement received from the SEC and (ii) copies of any written comments to the
Proxy Statement/Prospectus and the F-4 Registration Statement received from the
SEC, and in each case shall consult with each other in connection with the
preparation of written responses to such comments.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Teva
shall make, and Sicor shall cooperate in, all necessary filings with respect to
the Merger and the transactions contemplated thereby under the Securities Act
and all applicable Israeli securities laws and regulation and United States
state securities and &#147;blue sky&#148; laws.&#160;
Each party shall advise the other, promptly after receipt of notice
thereof, of the time of the effectiveness of the F-4 Registration Statement,
the filing of any supplement or amendment thereto, the issuance of any stop
order relating thereto, the suspension of the qualification of Teva ADSs
issuable in connection with the Merger for offering or sale in any
jurisdiction, or of any SEC request for an amendment to the Proxy
Statement/Prospectus or the F-4 Registration Statement, SEC comments thereon
and each party&#146;s responses thereto or SEC requests for additional
information.&#160; No amendment or supplement
to the Proxy Statement/Prospectus or the F-4 Registration Statement shall be
filed without the approval of both parties hereto, which approval shall not be
unreasonably withheld or delayed. &#160;If,
at any time prior to the Effective Time, Teva or Sicor should discover any
information relating to either party, or any of their respective Affiliates,
directors or officers, that should be set forth in an amendment or supplement
to the F-4 Registration Statement or the Proxy Statement/Prospectus, so that
the documents would not include any misstatement of a material fact or omit to
state any material fact necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading, the party that
discovers such information shall promptly notify the other party hereto and an
appropriate amendment or supplement describing such information shall be
promptly filed with the SEC and, to the extent required by Law, disseminated to
the stockholders of Teva and Sicor.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.6</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="AccountantsComfortLetters38"><u>Accountants&#146; Comfort Letters</u></a>.&#160; (a)&#160;
Teva shall use all commercially reasonable efforts to cause to be
delivered to Sicor two letters from Teva&#146;s independent public accountants, one
dated approximately the date on which the F-4 Registration Statement covering
the Teva ADSs to be issued in the Merger shall become effective and one dated
the Closing Date, each addressed to Sicor and Teva, in form reasonably
satisfactory to Sicor and customary in scope for comfort letters delivered by
independent public accountants in connection with similar Registration
Statements.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sicor
shall use all commercially reasonable efforts to cause to be delivered to Teva
two letters from Sicor&#146;s independent public accountants, one dated
approximately the date on which the F-4 Registration Statement covering the
Teva ADSs to be issued in the Merger shall become effective and one dated the
Closing Date, each addressed to Teva and Sicor, in form reasonably satisfactory
to Teva and customary in scope for comfort letters delivered by independent
public accountants in connection with similar Registration Statements.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.7</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="StockExchangeListing39"><u>Stock Exchange Listing</u></a>.&#160; Teva shall use all commercially reasonable
efforts to cause the Teva ADSs to be issued in connection with the Merger and
the Teva ADSs to be</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='42',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">reserved for issuance upon
exercise of the assumed Sicor Stock Options to be approved for quotation of the
Nasdaq National Market System subject to official notice of issuance.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.8</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="AffiliateLetters40"><u>Affiliate Letters</u></a>.&#160; Sicor has delivered to Teva a letter identifying all Persons who,
in the judgment of Sicor, may be deemed, at the time this Agreement is
submitted for adoption by the stockholders of Sicor, Affiliates of Sicor under
Rule 145 of the Securities Act.&#160; Sicor
shall promptly update such list as necessary to reflect any changes from the
date thereof.&#160; Sicor shall use all
commercially reasonable efforts to obtain a written agreement from each Person
referred to in Section&nbsp;3.5 as soon as practicable and, in any event, at
least ten (10) days prior to the Effective Time, substantially in the form of <u>Exhibit
A</u> hereto.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.9</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="ResaleRegistrationStatement41"><u>Resale Registration Statement</u></a>.&#160; Teva shall use all commercially reasonable
efforts to cause a registration statement on Form F-3 or any successor for or,
if Form F-3 or any successor form is not then available, to effect a
registration of all of the Teva ADSs acquired by Persons who may be deemed to
be affiliates of Sicor under Rule 145 of the Securities Act (&#147;<u>Affiliate
Stock</u>&#148;), or otherwise to include such Affiliate Stock on the F-4
Registration Statement (the &#147;<u>Resale Registration Statement</u>&#148;) covering
all shares of Affiliate Stock to be filed with the SEC<b><font style="font-weight:bold;">  </font></b>as soon as practicable
following the execution of this Agreement and to cause such Registration
Statement to become effective prior to or at the Effective Time.&#160; Teva shall use all commercially reasonable
efforts to keep the Resale Registration Statement effective until the earlier
of (a) the date which is two (2) years after the Effective Time, (b) the date
on which all persons who may be deemed to be Affiliates of Sicor under Rule 145
of the Securities Act no longer hold any shares of Affiliate Stock and (3) the
date such shares of Affiliate Stock may be sold within any three month period
pursuant to Rule 145.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.10</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="StockExchangeDelisting42"><u>Stock Exchange De-listing</u></a>.&#160; The Surviving Corporation shall use all
commercially reasonable efforts to cause the shares of Sicor Common Stock to be
removed from listing on the Nasdaq National Market System and de-registered
under the Exchange Act as soon as practicable following the Effective Time.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.11</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="Publicity1"><u>Publicity</u></a>.&#160;
The initial press release shall be a joint press release and thereafter
Sicor and Teva each shall consult with the other prior to issuing any press
releases or otherwise making public announcements with respect to the Merger
and the other transactions contemplated hereby and by the Stockholders
Agreement and prior to making any filings with any third party and/or any
Governmental Entity with respect thereto, except as may be required by Law or
by obligations pursuant to any listing agreement with or rules of any national
securities exchange or national market system.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.12</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="BenefitsandOtherEmployeeMatters2"><u>Benefits and Other Employee Matters</u>.</a></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Employee
Benefits</u>. &#160;Teva agrees that, during
the period commencing at the Effective Time and ending on the second
anniversary thereof, the current and former employees of Sicor and its
Subsidiaries who are receiving benefits under the Sicor Compensation and
Benefit Plans (&#147;<u>Affected Employees</u>&#148;) will continue to be provided with
benefits under employee benefit plans that are the same or substantially
comparable in the aggregate to either (i) those currently provided by Sicor and
its Subsidiaries to such employees as of the Closing Date or</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">43</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='43',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii) those provided by Teva and
its Subsidiaries to similarly situated employees from time to time during such
two (2) year period.&#160; Following the
Effective Time, Teva shall cause service by Affected Employees of Sicor and its
Subsidiaries (and any predecessor entities) to be taken into account for
purposes of eligibility to participate, eligibility to commence benefits,
vesting and, solely for purposes of severance and vacation benefits, benefit
accruals (except to the extent such treatment would result in duplicative
accrual of benefits for the same period of service) under the Compensation and
Benefit Plans or any other benefit plans of Teva or its Subsidiaries in which
such employees participate.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">From and after the Effective Time, Teva shall, with respect to Affected
Employees entitled to participate in Compensation and Benefit Plans subject to
United States law, (i) cause to be waived any pre-existing condition
limitations under welfare benefit plans, policies or practices of Teva or its
Subsidiaries in which employees of Sicor or its Subsidiaries participate and
(ii) cause to be credited any deductibles and out-of-pocket expenses incurred
by such employees and their beneficiaries and dependents during the portion of
the calendar year prior to participation in the benefit plans provided by Teva
and its Subsidiaries.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva shall, and shall cause the Surviving Corporation to, honor all
employee benefit obligations to current and former employees and directors
under the Sicor Compensation and Benefit Plans.&#160; Teva shall cause the Surviving Corporation to assume in writing
the obligations under the employment agreements and change of control
agreements to which Sicor is a party at the Effective Time as required by such
agreements.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva agrees that the transactions contemplated by this Agreement meet
the definition of, and shall constitute, a &#147;change in control&#148; under each Sicor
Compensation and Benefit Plan listed in Section&nbsp;5.1(h)(i)(B) of Sicor
Disclosure Schedules.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Employees</u>.&#160; It is the present intention of Teva and
Sicor that following the Effective Time, there will be no significant
involuntary reductions in workforce at the Surviving Corporation or its
Subsidiaries; <i><font style="font-style:italic;">provided, however</font></i>, that if any significant reductions in
workforce in respect of employees of the Surviving Corporation and its
Subsidiaries become necessary, they shall be made on a fair and equitable
basis, in light of the circumstances and the objectives to be achieved, to be
determined by Teva in its reasonable discretion.&#160; Any employee whose employment is terminated or job is eliminated
by Teva, the Surviving Corporation or any of their respective Subsidiaries
shall be entitled to participate on a fair and equitable basis in the job
opportunity and employment placement programs offered by Teva, the Surviving
Corporation or any of their respective Subsidiaries at such employee&#146;s local
level.&#160; Any workforce reductions carried
out following the Effective Time by Teva or the Surviving Corporation and their
respective Subsidiaries shall be done in all material respects in accordance
with all applicable collective bargaining agreements, and all Laws and
regulations governing the employment relationship and termination thereof including,
without limitation, the Worker Adjustment and Retraining Notification Act and
regulations promulgated thereunder, and any comparable state or local Law.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.13</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="IndemnificationDirectorsandOfficers3"><u>Indemnification; Directors&#146; and
Officers</u></a><u>&#146; Insurance</u>.&#160;
(a)&#160; Teva shall indemnify and
hold harmless (i) to the fullest extent permitted under applicable Law and (ii)
without</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">44</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='44',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">limitation of clause (i), as
required pursuant to the existing indemnity agreements of Sicor (and Teva also
shall advance attorneys&#146; fees and expenses as incurred (x) to the fullest
extent permitted under applicable Law and (y) without limitation of clause (x),
as required pursuant to the existing indemnity agreements of Sicor, provided,
if and only to the extent required by the DGCL and such existing indemnity
agreements, the Person to whom expenses are advanced provides an undertaking to
repay such advances if it is ultimately determined that such Person is not
entitled to indemnification), each present and former director, officer and
employee of Sicor and its Subsidiaries (collectively, the &#147;<u>Indemnified
Parties</u>&#148;) against any costs or expenses (including attorneys&#146; fees and
expenses), judgments, fines, losses, claims, settlements, damages or
liabilities (collectively, &#147;<u>Costs</u>&#148;) incurred in connection with any
claim, action, suit, proceeding or investigation, whether civil, criminal,
administrative or investigative, arising out of or pertaining to matters
existing or occurring at or prior to the Effective Time, including the
transactions contemplated hereby.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Any
Indemnified Party wishing to claim indemnification under paragraph (a) of this
Section&nbsp;7.13, upon receiving written notification of any such claim,
action, suit, proceeding or investigation, shall promptly notify Teva thereof,
but the failure to so notify shall not relieve Teva of any liability it may
have to such Indemnified Party except if, and only to the extent that, such
failure materially and irreversibly prejudices Teva.&#160; In the event of any such claim, action, suit, proceeding or
investigation (whether arising before or after the Effective Time), (i) Teva
shall pay the fees and expenses of counsel selected by the Indemnified Party,
promptly after statements therefor are received, and otherwise advance to such
Indemnified Party upon request reimbursement of documented expenses reasonably
incurred, (ii) Teva will cooperate in the defense of any such matter, and (iii)
any determination required to be made with respect to whether an Indemnified
Party&#146;s conduct complies with the standards set forth under applicable Law
shall be made by independent counsel mutually acceptable to Teva and the
Indemnified Party; <i><font style="font-style:italic;">provided, however</font></i>, that (A) Teva shall be
obligated pursuant to this Section&nbsp;7.13(b) to pay for only one firm of
counsel for all Indemnified Parties in any jurisdiction, except to the extent
there is, in the opinion of counsel to an Indemnified Party, under applicable
standards of professional conduct, a conflict on any significant issue between
the positions of such Indemnified Party and any other Indemnified Party or
Indemnified Parties, in which case each Indemnified Party with a conflicting
position on a significant issue shall be entitled to retain separate counsel
mutually satisfactory to Teva and such Indemnified Party, (B) the Indemnified
Parties shall cooperate in the defense of any such matter and (C) Teva shall
not be liable for any settlement effected without its prior written consent
(which consent may not be unreasonably withheld or delayed).</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>As
of the Effective Time, Teva or Merger Sub shall have purchased directors&#146; and
officers&#146; liability insurance coverage for Sicor&#146;s directors and officers for a
period of six (6) years after the Effective Time which provides runoff coverage
on the same terms and conditions as that currently provided by Sicor for its
directors and officers (as disclosed to Teva prior to the date hereof) but
broadened to include entity securities coverage, in an amount of $50 million;
provided, that Teva or Merger Sub shall not be required to pay an aggregate
premium in excess of $6 million; and, provided, further, that if Teva or Merger
Sub have not purchased such limits of insurance at such cost by the 30th day
before the Effective Time, Sicor will purchase as much coverage as is available
for such amount.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">45</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='45',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
Certificate of Incorporation and By-Laws of the Surviving Corporation shall
include provisions for exculpation of director and officer liability and
indemnification on the same basis as set forth in Sicor&#146;s certificate of
incorporation and by-laws in effect on the date hereof.&#160; For six (6) years after the Effective Time,
Teva shall cause the Surviving Corporation to maintain in effect the provisions
in its Certificate of Incorporation providing for indemnification of
Indemnified Parties, with respect to facts and circumstances occurring at or
prior to the Effective Time, to the fullest extent permitted from time to time
under the DGCL, which provisions shall not be amended except as required by
applicable Law or except to make changes permitted by applicable Law that would
increase the scope of the Indemnified Parties&#146; indemnification rights
thereunder.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If
Teva or the Surviving Corporation or any of its successors or assigns shall
(i)&#160; consolidate with or merge into any
other Person and shall not be the continuing or surviving corporation or entity
of such consolidation or merger or (ii) transfer all or substantially all of
its properties and assets to any Person, then, and in each such case, proper
provisions shall be made so that the successors and assigns of Teva or the
Surviving Corporation, as the case may be, shall assume all of the obligations
of Teva and the Surviving Corporation set forth in this Section&nbsp;7.13.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
rights of each Indemnified Party under this Section&nbsp;7.13 shall be in
addition to any right such Person might have under the certificate of
incorporation or by-laws of Sicor or any of its Subsidiaries, or under
applicable Law (including the DGCL) or under any agreement of any Indemnified
Party with Sicor or any of its Subsidiaries.&#160;
The provisions of this Section&nbsp;7.13 are intended to be for the
benefit of, and shall be enforceable by, each of the Indemnified Parties, their
respective heirs and representatives.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.14</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="Expenses4"><u>Expenses</u></a>.&#160;
Subject to Section&nbsp;9.5(b) and (c), whether or not the Merger is
consummated, all costs and expenses incurred in connection with the Merger and
the other transactions contemplated hereby shall be paid by the party incurring
such expense, except that each of Sicor and Teva shall bear and pay one-half of
the costs and expenses incurred in connection with the filing, printing and
mailing of the Proxy Statement/Prospectus (including any SEC filing fees).</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.15</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="TakeoverStatute5"><u>Takeover Statute</u></a>.&#160; If any Takeover Statute is or may become applicable to the Merger
or the other transactions contemplated hereby or by the Stockholders Agreement,
each of Teva, Sicor and Merger Sub and their respective Board of Directors,
shall grant such approvals and take such actions as are necessary so that such
transactions may be consummated as promptly as practicable hereafter on the
terms contemplated hereby and otherwise act to eliminate or minimize the
effects of such statute or regulation on such transactions.&#160;&#160; &#147;<u>Takeover Statute</u>&#148; shall mean any
restrictive provision of any applicable &#147;fair price,&#148; &#147;moratorium,&#148; &#147;control
share acquisition,&#148; &#147;interested stockholder&#148; or other similar anti-takeover
Law, including Section&nbsp;203 of the DGCL.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.16</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="TevaVote6"><u>Teva Vote</u></a>.&#160;
Teva shall vote (or consent with respect to) or cause to be voted (or a
consent to be given with respect to) any shares of Sicor Common Stock and any
shares of capital stock of Merger Sub beneficially owned by it or any of its
affiliates (as such term is defined under the Exchange Act) or with respect to
which it or any of such affiliates has the power (by</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">46</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='46',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">agreement, proxy or otherwise)
to cause to be voted (or to provide a consent), in favor of the approval of this
Agreement and the transactions contemplated hereby at any meeting of
stockholders of Sicor or Merger Sub, respectively, at which this Agreement
shall be submitted for approval and at all adjournments or postponements
thereof (or, if applicable, by any action of stockholders of either Sicor or
Merger Sub by consent in lieu of a meeting).</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.17</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="Section16Matters7"><u>Section&nbsp;16 Matters</u></a>.&#160; Prior to the Effective Time, Teva and Sicor
shall take all such steps as may be required and permitted to cause the
transactions contemplated by this Agreement, including any dispositions of
shares of Sicor Common Stock or acquisitions of Teva ADSs (including derivative
securities with respect to such shares of Sicor Common Stock or Teva ADSs) by
each individual who is or will be subject to the reporting requirements of
Section&nbsp;16(a) of the Exchange Act with respect to Sicor to be exempt under
Rule 16b-3 promulgated under the Exchange Act.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.18</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="CorporateGovernance8"><u>Corporate Governance</u>.</a></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Director</u>.&#160; Within the thirty (30) day period following
the Effective Time, Teva shall use all commercially reasonable efforts to cause
the Teva Board of Directors, subject to applicable Law, to duly appoint the
individual listed on Schedule&nbsp;7.18(a) as a member of the class of
directors of Teva set forth opposite such individual&#146;s name on
Schedule&nbsp;7.18(a).</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Case</u>.&#160; In the event that Sicor has not settled <u>Terry
Klein, Derivatively on behalf of</u>  <u>SICOR Inc., vs. Carlo Salvi, Rakepoll
Finance N.V, Karbona Industries Ltd., Bio-Rakepoll N.V., Michael Cannon, and
SICOR Inc.</u> (the &#147;<u>Case</u>&#148;) by the Effective Time, Teva agrees to
consult with Pillsbury Winthrop LLP for purposes of determining appropriate
actions with respect to litigating or settling the Case or any similar claim.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><a name="Articleviii"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;VIII</font></a></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">CONDITIONS</font></u></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="ConditionstoEachPartysObligationto11"><u>Conditions to Each Party&#146;s Obligation
to</u></a><u> Effect the Merger</u>.&#160;
The respective obligation of each party to effect the Merger is subject
to the satisfaction or waiver at or prior to the Effective Time of each of the
following conditions:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Stockholder
Approval</u>.&#160; The Sicor Requisite Vote shall
have been obtained.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>HSR</u>.&#160; The waiting period applicable to the
consummation of the Merger under the HSR Act shall have expired or been earlier
terminated.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Other
Regulatory Consents</u>.&#160; The Teva
Required Statutory Approvals and Sicor Required Statutory Approvals shall have
been obtained at or prior to the Effective Time, such approvals shall have
become Final Orders (as hereinafter defined), and no Final Order shall impose
terms or conditions that would have, or would be reasonably likely to have a
Teva Material Adverse Effect or Sicor Material Adverse Effect on Teva or Sicor
(together with the Subsidiaries of Teva and Sicor, respectively) taken as a
whole, respectively.&#160; A &#147;<u>Final Order</u>&#148;
means action by the relevant regulatory authority that has not been reversed,
stayed, enjoined, set</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">47</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='47',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">aside, annulled or suspended,
with respect to which any waiting period prescribed by Law before the
transactions contemplated hereby may be consummated has expired, and as to
which all conditions to the consummation of such transactions prescribed by
Law, regulation or order have been satisfied.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Injunction</u>.&#160; No court or Governmental Entity of competent
jurisdiction shall have enacted, issued, promulgated, enforced or entered any
statute, Law, ordinance, rule, regulation, judgment, decree, injunction or
other order that is in effect and permanently enjoins or otherwise prohibits
consummation of the Merger, the Distribution or the other Transactions
(collectively, an &#147;<u>Order</u>&#148;); provided, however, that prior to invoking
this condition each party agrees to comply with Section&nbsp;7.4.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>F-4
Registration Statement</u>.&#160; The F-4
Registration Statement shall have been declared effective by the SEC and no
stop order suspending the effectiveness of the F-4 Registration Statement shall
be in effect and no proceedings for such purpose shall be pending before or
threatened by the SEC, and all Israeli, United States state securities and
&#147;blue sky&#148; authorizations necessary to carry out the transactions contemplated
hereby shall have been obtained and be in effect.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="ConditionstoObligationsofTevaandMe12"><u>Conditions to Obligations of Teva
and Me</u></a><u>rger Sub</u>.&#160; The
obligations of Teva and Merger Sub to effect the Merger are also subject to the
satisfaction or waiver by Teva at or prior to the Effective Time of the
following conditions:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Representations
and Warranties</u>.&#160; The representations
and warranties of Sicor set forth in this Agreement shall be true and correct
as of the Closing Date as though made on and as of the Closing Date (except to
the extent any such representation or warranty expressly speaks as of an
earlier date, which representations and warranties shall be true and correct as
of such date in the same manner as specified above), except for failures to be
true and correct that individually or in the aggregate would not reasonably be
likely to have a Sicor Material Adverse Effect; provided, that for purposes of
determining whether the condition in this Section&nbsp;8.2(a) is satisfied,
&#147;Sicor Material Adverse Effect&#148; and any other materiality qualification
contained in such representations and warranties shall be ignored, and Teva
shall have received a certificate signed on behalf of Sicor by the chief
executive officer and the chief financial officer of Sicor to such effect.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Performance
of Obligations of Sicor</u>.&#160; Sicor
shall have performed in all material respects at or prior to the Closing Date
all material obligations required to be performed by it under this Agreement at
or prior to the Closing Date, and Teva shall have received a certificate signed
on behalf of Sicor by the chief executive officer and the chief financial
officer of Sicor to such effect.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No
Material Adverse Change</u>.&#160; Sicor and
its Subsidiaries shall not have suffered from the date of this Agreement any
change or other event that, individually or in the aggregate, would reasonably
be expected to have a Sicor Material Adverse Effect.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">48</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='48',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="ConditionstoObligationofSicor13"><u>Conditions to Obligation of Sicor</u></a>.&#160; The obligation of Sicor to effect the Merger
is also subject to the satisfaction or waiver by Sicor at or prior to the
Effective Time of the following conditions:</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Representations
and Warranties</u>.&#160; The representations
and warranties of Teva and Merger Sub set forth in this Agreement shall be true
and correct as of the Closing Date as though made on and as of the Closing Date
(except to the extent any such representation or warranty expressly speaks as
of an earlier date, which representations and warranties shall be true and
correct as of such date in the same manner as specified above), except for
failures to be true and correct that individually or in the aggregate would not
reasonably be likely to have a Teva Material Adverse Effect; provided, that for
purposes of determining whether the condition in this Section&nbsp;8.3(a) is
satisfied, &#147;Teva Material Adverse Effect&#148; and any other materiality
qualification contained in such representations and warranties shall be
ignored, and Sicor shall have received a certificate signed on behalf of Teva
and Merger Sub by the chief executive officer and the chief financial officer
of each of Teva and Merger Sub to such effect.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Performance
of Obligations of Teva and Merger Sub</u>.&#160;
Each of Teva and Merger Sub shall have performed in all material
respects all material obligations required to be performed by it under the
Agreement at or prior to the Closing Date, and Sicor shall have received a
certificate signed on behalf of Teva and Merger Sub by the chief executive
officer and the chief financial officer of each of Teva and Merger Sub to such
effect.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No
Material Adverse Change</u>.&#160; Teva and
its Subsidiaries shall not have suffered from the date of this Agreement any
change or other event that, individually or in the aggregate, would reasonably
be expected to have a Teva Material Adverse Effect.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Stock
Exchange Listing</u>.&#160; The Teva ADSs to
be issued in connection with the Merger and the Teva ADSs reserved for issuance
upon exercise of the assumed Sicor Options shall have been approved for
quotation on the Nasdaq National Market System, subject to official notice of
issuance.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><a name="Articleix"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;IX</font></a></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">TERMINATION</font></u></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="TerminationbyMutualConsent16"><u>Termination by Mutual Consent</u></a>.&#160; This Agreement may be terminated and the
Merger may be abandoned at any time prior to the Effective Time, whether before
or after receipt of Sicor Requisite Vote, by mutual written consent of Sicor
and Teva by action of their respective Boards of Directors.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="TerminationbyEitherTevaorSicor17"><u>Termination by Either Teva or Sicor</u></a>.&#160; This Agreement may be terminated and the
Merger may be abandoned at any time prior to the Effective Time by action of
the Board of Directors of either Teva or Sicor if</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the
Merger shall not have been consummated by April&nbsp;30, 2004, whether such
date is before or after the date of receipt of the Sicor Requisite Vote (the &#147;<u>Termination
Date</u>&#148;), <i><font style="font-style:italic;">provided</font></i>
that the Termination Date shall be automatically extended for six (6) months
if, on the</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">49</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='49',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Termination Date any of the
conditions set forth in Section&nbsp;8.1(b) or (c) shall not have been
satisfied or waived but (i) each of the other conditions to the consummation of
the Merger set forth in Article&nbsp;VIII has been satisfied or waived or
remains capable of satisfaction, and (ii) any approvals required by Section&nbsp;8.1(b)
or (c) that have not yet been obtained are being pursued diligently and in good
faith;<i><font style="font-style:italic;">
provided</font></i>, that the right to terminate this Agreement pursuant to
this clause (a) shall not be available to any party that has breached in any
material respect its obligations under this Agreement in any manner that shall
have proximately caused the occurrence of the failure of the Merger to be
consummated;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the
Sicor Requisite Vote shall not have been obtained at a meeting duly convened
therefor or at any adjournment or postponement thereof, or</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any
Order permanently restraining, enjoining or otherwise prohibiting consummation
of the Merger shall become final and non-appealable after such party has used
all commercially reasonable efforts to have such Order removed, repealed or
overturned (whether before or after the receipt of the Sicor Requisite Vote).</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="TerminationbySicor18"><u>Termination by Sicor</u></a>.&#160; This Agreement may be terminated and the
Merger may be abandoned by action of the Board of Directors of Sicor at any
time prior to (a) receipt of the Sicor Requisite Vote, if the Board of
Directors of Sicor shall take any action contemplated by clause (D) or (E) of
Section&nbsp;7.2; <i><font style="font-style:italic;">provided, however</font></i>, that (i) Sicor complies with
Section&nbsp;7.2 and (ii) the termination pursuant to this Section&nbsp;9.3(a)
shall not be effective unless Sicor shall at or prior to the time of such
termination make the payment required by Section&nbsp;9.5(b), or (b) the
Effective Time, whether before or after receipt of the Sicor Requisite Vote, if
there has been a material breach by Teva or Merger Sub of any material
representation, warranty, covenant or agreement contained in this Agreement
such that the condition in Section&nbsp;8.2(a) or Section&nbsp;8.2(b), as the
case may be, would not be satisfied and that is not curable or, if curable, is
not cured within twenty (20) days after written notice of such breach is given
by Sicor to the party committing such breach.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="TerminationbyTeva19"><u>Termination by Teva</u></a>.&#160; This Agreement may be terminated and the
Merger may be abandoned by action of the Board of Directors of Teva at any time
prior to the Effective Time if (a) the Board of Directors of Sicor takes any
action contemplated by clause (D) or (E) of Section&nbsp;7.2, (b) the Board of
Directors of Sicor shall have withdrawn or materially and adversely modified
its adoption of this Agreement or its recommendation that the stockholders of
Sicor approve this Agreement (it being understood, however, that for all
purposes of this Agreement, and without limitation, the fact that Sicor, in
compliance with this Agreement, has supplied any Person with information
regarding Sicor or has entered into discussions or negotiations with such
Person as permitted by this Agreement, or the disclosure of such facts, shall
not be deemed a withdrawal or modification of Sicor&#146;s Board of Directors&#146;
recommendation of the Merger or this Agreement), (c) a tender offer or exchange
offer that, if successful, would result in any Person or &#147;group&#148; becoming a
&#147;beneficial owner&#148; (such terms having the meaning in this Agreement as is
ascribed under Regulation 13D under the Exchange Act) of thirty percent (30%)
or more of the outstanding shares of Sicor Common Stock is commenced (other
than by Teva or an affiliate of Teva) and the Board of Directors of Sicor
recommends that the stockholders of Sicor tender their shares in such tender or
exchange offer, (d) for any reason Sicor fails to call or hold the Sicor</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">50</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='50',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">stockholders meeting
contemplated under Section&nbsp;7.3 within six months of the date hereof (provided
that if the F-4 Registration Statement shall not have become effective for
purposes of the Securities Act by the date that is twenty (20) business days
(counting, for purposes of this clause (d), days that&#160; are not business days in Tel Aviv but are business days in New
York) prior to the date that is five months from the date hereof, then such
date shall be extended by such number of days equal to the date from the end of
such five-month period until the effective date of such F-4 Registration Statement)<i><font style="font-style:italic;">; provided</font></i>,
that Teva&#146;s right to terminate this Agreement pursuant to this clause (d) shall
not be available to Teva if it has breached in any material respect its
obligations under this Agreement in any manner that shall have proximately
caused the occurrence of the failure of the Sicor stockholders meeting to be
called or held, or (e) there has been a material breach by Sicor of any
material representation, warranty, covenant or agreement contained in this
Agreement such that the condition in Section&nbsp;8.3(a) or
Section&nbsp;8.3(b), as the case may be, would not be satisfied and that is not
curable or, if curable, is not cured within twenty (20) days after written
notice of such breach is given by Teva to Sicor.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="EffectofTerminationandAbandonment20"><u>Effect of Termination and
Abandonment</u></a>.&#160; (a)&#160; In the event of termination of this
Agreement and the abandonment of the Merger pursuant to this Article&nbsp;IX,
this Agreement (other than as set forth in Section&nbsp;10.1) shall become void
and of no effect with no liability on the part of any party hereto (or of any
of its directors, officers, employees, agents, legal and financial advisors or
other representatives); <i><font style="font-style:italic;">provided, however</font></i>, that no such
termination shall relieve any party hereto of any liability or damages
resulting from any breach of this Agreement.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In
the event that this Agreement is terminated (A) by either party pursuant to
Section&nbsp;9.2(b), provided that at the time of the meeting referred to in
Section&nbsp;9.2(b) an Acquisition Proposal or other announcement of any
intention with respect to an Acquisition Proposal shall have been made (even if
such Acquisition Proposal had been rejected or withdrawn), (B) by Sicor
pursuant to Section&nbsp;9.3(a), or (C) by Teva pursuant to
Section&nbsp;9.4(a), (b), (c) or (d), then, in each case of clauses (A) - (C),
(X) Sicor shall promptly, but in no event later than two (2) business days
after the date of such termination, pay Teva a fee in the amount of $5 million
to reimburse it for expenses incurred in connection with this Agreement and the
transactions contemplated hereby (which expenses need not be documented) and
(Y) if, within twelve (12) months after any such termination Sicor enters into
a definitive agreement with respect to or consummates a transaction
contemplated by an Acquisition Proposal, then Sicor shall promptly, but in no
event later than two (2) business days after the date of such entering into a
definitive agreement or of such consummation, as applicable, pay Teva a
termination fee (as liquidated damages) of $120 million (which includes charges
and expenses incurred by Teva or Merger Sub in connection with this Agreement
and the transactions contemplated hereby).&#160;
Any such payment shall be made by wire transfer of same day funds to an
account previously designated in writing by Teva to Sicor.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The
parties acknowledge that the agreement contained in Section&nbsp;9.5(b) is an
integral part of the transactions contemplated by this Agreement, and that,
without this agreement Teva would not have entered into this Agreement;
accordingly, if Sicor fails to promptly pay any amounts due pursuant to
Section&nbsp;9.5(b), and in order to obtain such payment Teva commences a suit
which results in a judgment against Sicor for payment of all or a portion of a
termination fee, Sicor shall pay to Teva its costs and expenses (including its
reasonable</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='51',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">attorneys&#146; fees) incurred in
connection with such suit, together with interest from the date such payment
was due on the amounts owed at the prime rate in effect from time to time and
quoted in <i><font style="font-style:italic;">The
Wall Street Journal</font></i> during such period.&#160; The payment of such termination fee pursuant to this
Section&nbsp;9.5 shall be the sole and exclusive remedy of Teva with respect to
the facts and circumstances giving rise to such payment obligation (or facts
and circumstances which would have given rise to such payment but for a breach
of this Agreement by Teva).</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><a name="Articlex"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;X</font></a></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">MISCELLANEOUS AND GENERAL</font></u></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="Survival23"><u>Survival</u></a>.&#160;
This Article&nbsp;X and the agreements of Sicor, Teva and Merger Sub
contained in Sections 7.10 (Stock Exchange De-listing), 7.12 (Benefits and
Other Employee Matters), 7.13 (Indemnification; Directors&#146; and Officers&#146;
Insurance) and 7.14 (Expenses) and those other covenants and agreements
contained herein that by their terms apply, or that are to be performed in
whole or in part, after the Effective Time shall survive the consummation of
the Merger.&#160; This Article&nbsp;X, the
agreements of Sicor, Teva and Merger Sub contained in Section&nbsp;7.14
(Expenses), Section&nbsp;9.5 (Effect of Termination and Abandonment) and the
Confidentiality Agreement shall survive the termination of this Agreement.&#160; All other representations, warranties,
covenants and agreements in this Agreement shall not survive the consummation
of the Merger or the termination of this Agreement.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="ModificationorAmendment24"><u>Modification or Amendment</u></a>.&#160; Subject to the provisions of applicable Law,
at any time prior to the Effective Time, the parties hereto may modify or amend
this Agreement, by written agreement executed and delivered by duly authorized
officers of the respective parties.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="WaiverofConditions25"><u>Waiver of Conditions</u></a>.&#160; The conditions to each of the parties&#146;
obligations to consummate the Merger are for the sole benefit of such party and
may be waived by such party in whole or in part to the extent permitted by
applicable Law.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="Counterparts26"><u>Counterparts</u></a>.&#160;
This Agreement may be executed in any number of counterparts, each such
counterpart being deemed to be an original instrument, and all such
counterparts shall together constitute the same agreement.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="GOVERNINGLAWANDVENUE27"><u>GOVERNING LAW AND VENUE</u></a>.&#160; PURSUANT TO SECTION&nbsp;5-1401 OF THE
GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK, THIS AGREEMENT SHALL BE
INTERPRETED, CONSTRUED AND GOVERNED BY AND IN ACCORDANCE WITH THE LAW OF THE
STATE OF NEW YORK.&#160; The parties hereby
irrevocably submit to the jurisdiction of the courts of the State of New York
and the Federal courts of the United States of America located in the State of
New York in each case in the borough of Manhattan solely in respect of the
interpretation and enforcement of the provisions of this Agreement and of the
documents referred to in this Agreement, and in respect of the Transactions,
and hereby waive, and agree not to assert, as a defense in any action, suit or
proceeding for the interpretation or enforcement hereof or of any such document,
that it is not subject thereto or that such action, suit or proceeding may not
be brought or is not maintainable in said courts or that the venue thereof may
not be appropriate or that this Agreement or any such</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">52</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='52',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">document may not be enforced in
or by such courts, and the parties hereto irrevocably agree that all claims
with respect to such action or proceeding shall be heard and determined in such
a State of New York or Federal court.&#160;
The parties hereby consent to and grant any such court jurisdiction over
the Person of such parties and over the subject matter of such dispute and
agree that mailing of process or other papers in connection with any such
action or proceeding in the manner provided in Section&nbsp;10.6 or in such
other manner as may be permitted by Law shall be valid and sufficient service
thereof.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.6</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="Notices28"><u>Notices</u></a>.&#160; Any
notice, request, instruction or other document to be given hereunder by any
party to the others shall be in writing and delivered personally or sent by
registered or certified mail, postage prepaid, or by facsimile (upon receipt of
electronic or telephonic confirmation of successful transmission):</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:1.0in;width:86.68%;">
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">if to Teva or Merger Sub,</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva Pharmaceutical Industries Limited</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5 Basel Street</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Petach Tikva&#160; 49131</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Israel</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160; Chief Executive
  Officer</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Telephone:&#160; 011 972 3 926 7267</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Facsimile: 011 972 3 924 6026</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">with copies to</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva Pharmaceutical Industries Limited</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5 Basel Street</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Petach Tikva&#160; 49131</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Israel</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160; General Counsel</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Telephone:&#160; 011 972 3 926 7267</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Facsimile: 011 972 3 926 7429</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva Pharmaceuticals USA, Inc.</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1090 Horsham Road</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">North Wales, Pennsylvania&#160;
  19454</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160; General Counsel</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Telephone:&#160; (215) 591-3000</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Facsimile: (215) 591-8813</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Willkie Farr &amp; Gallagher LLP</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">787 Seventh Avenue</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">New York, NY 10019-6099</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160; Peter H. Jakes,
  Esq.</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Telephone:&#160; (212) 728-8000</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Facsimile: (212) 728-8111</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">53</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='53',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:1.0in;width:86.68%;">
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">if to Sicor,</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SICOR Inc.</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19 Hughes</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Irvine, CA&#160; 92618</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160; Chief Executive
  Officer</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Telephone:&#160; (949) 455-4700</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Facsimile: (949) 455-4744</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">with a copy to</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pillsbury Winthrop LLP</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">50 Fremont Street</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">San Francisco, California&#160; 94105</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160; Thomas E. Sparks,
  Jr., Esq.</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Telephone:&#160; (415) 983-1000</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Facsimile:&#160;&#160; (415) 983-1200</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">or to such other Persons or addresses as may be designated in writing
by the party to receive such notice as provided above.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.7</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="EntireAgreementNOOTHERREPRESENTATIO29"><u>Entire Agreement; NO OTHER
REPRESENTATIO</u></a><u>NS</u>.&#160; This
Agreement (including any exhibits hereto), Sicor Disclosure Schedules, the Teva
Disclosure Schedules and the Confidentiality and Standstill Agreement, dated
June&nbsp;19, 2003, between Teva and Sicor, as amended (the &#147;<u>Confidentiality
Agreement</u>&#148;), constitute the entire agreement by and among the parties
hereto, and supersede all other prior agreements, understandings,
representations and warranties both written and oral, among the parties, with
respect to the subject matter hereof.&#160;
EACH PARTY HERETO AGREES THAT, EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES
CONTAINED IN THIS AGREEMENT, NEITHER TEVA AND MERGER SUB NOR SICOR MAKES ANY
OTHER REPRESENTATIONS OR WARRANTIES, AND EACH HEREBY DISCLAIMS ANY OTHER
REPRESENTATIONS OR WARRANTIES MADE BY ITSELF OR ANY OF ITS RESPECTIVE OFFICERS,
DIRECTORS, EMPLOYEES, AGENTS, FINANCIAL AND LEGAL ADVISORS OR OTHER
REPRESENTATIVES, WITH RESPECT TO THE EXECUTION AND DELIVERY OF THIS AGREEMENT
OR THE TRANSACTIONS, NOTWITHSTANDING THE DELIVERY OR DISCLOSURE TO THE OTHER OR
THE OTHER&#146;S REPRESENTATIVES OF ANY DOCUMENTATION OR OTHER INFORMATION WITH
RESPECT TO ANY ONE OR MORE OF THE FOREGOING.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.8</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="NoThirdPartyBeneficiaries30"><u>No Third-Party Beneficiaries</u></a>.&#160; Other than with respect to the matters set
forth in Section&nbsp;7.13 (Indemnification; Directors&#146; and Officers&#146;
Insurance), this Agreement is not intended to confer upon any Person other than
the parties hereto any rights or remedies hereunder.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">54</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='54',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.9</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="ObligationsofTevaandofSicor31"><u>Obligations of Teva and of Sicor</u></a>.&#160; Except as otherwise specifically provided
herein, whenever this Agreement requires a Subsidiary of Teva to take any
action, such requirement shall be deemed to include an undertaking on the part
of Teva to cause such Subsidiary to take such action.&#160; Whenever this Agreement requires a Subsidiary of Sicor to take
any action, such requirement shall be deemed to include an undertaking on the
part of Sicor to cause such Subsidiary to take such action and, after the
Effective Time, on the part of the Surviving Corporation to cause such
Subsidiary to take such action.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.10</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="Severability32"><u>Severability</u></a>.&#160;
The provisions of this Agreement shall be deemed severable and the
invalidity or unenforceability of any provision shall not affect the validity
or enforceability of the other provisions hereof.&#160; If any provision of this Agreement, or the application thereof to
any Person or any circumstance, is invalid or unenforceable, (a) a suitable and
equitable provision shall be substituted therefor in order to carry out, so far
as may be valid and enforceable, the intent and purpose of such invalid or unenforceable
provision and (b) the remainder of this Agreement and the application of such
provision to other Persons or circumstances shall not be affected by such
invalidity or unenforceability, nor shall such invalidity or unenforceability
affect the validity or enforceability of such provision, or the application
thereof, in any other jurisdiction.</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.11</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="Interpretation33"><u>Interpretation</u></a>.&#160; The table of contents and headings herein are for convenience of
reference only, do not constitute part of this Agreement and shall not be
deemed to limit or otherwise affect any of the provisions hereof.&#160; Where a reference in this Agreement is made
to a Section&nbsp;or Exhibit, such reference shall be to a Section&nbsp;of or
Exhibit to this Agreement unless otherwise indicated.&#160; Whenever the words &#147;include,&#148; &#147;includes&#148; or &#147;including&#148; are used
in this Agreement, they shall be deemed to be followed by the words &#147;without
limitation.&#148;</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.12</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><a name="Assignment34"><u>Assignment</u></a>.&#160;
This Agreement shall not be assignable by operation of Law or otherwise;
<i><font style="font-style:italic;">provided,
however</font></i>, that Teva may designate, by written notice to Sicor,
another wholly-owned direct or indirect subsidiary to be a constituent
corporation in lieu of Merger Sub, so long as such designation would not
reasonably be expected to (i) impose any material delay in the obtaining of, or
significantly increase the risk of not obtaining any Teva Required Statutory
Approval or Sicor Required Statutory Approval or the expiration or termination
of any applicable waiting period, (ii) significantly increase the risk of any
Governmental Entity entering an order prohibiting the consummation of the
Merger, (iii) significantly increase the risk of not being able to remove any
such order on appeal or otherwise or (iv) materially delay the consummation of
the Merger.&#160; If the requirements of the
previous sentence are met and Teva wishes to designate another wholly-owned
direct or indirect subsidiary to be a constituent corporation in lieu of Merger
Sub, then, all references herein to Merger Sub shall be deemed references to
such other subsidiary, except that all representations and warranties made
herein with respect to Merger Sub as of the date of this Agreement shall be
deemed representations and warranties made with respect to such other
subsidiary as of the date of such designation.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">55</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='55',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, this Agreement has been duly executed, acknowledged
and delivered by the duly authorized officers of the parties hereto as of the
date first written above.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="40%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:40.76%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SICOR INC.</font></p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="40%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:40.76%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="40%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:40.76%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.4%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
  </td>
  <td width="30%" valign="top" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:30.46%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.9%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.4%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="37%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:37.36%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.4%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="37%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:37.36%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="40%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:40.76%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="40%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:40.76%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TEVA PHARMACEUTICAL INDUSTRIES<br>
  LIMITED</font></p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="40%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:40.76%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="40%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:40.76%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.4%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
  </td>
  <td width="30%" valign="top" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:30.46%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.9%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.4%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="37%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:37.36%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.4%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="37%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:37.36%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.4%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="37%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:37.36%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.4%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="37%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:37.36%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.4%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
  </td>
  <td width="30%" valign="top" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:30.46%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.9%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.4%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="37%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:37.36%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.4%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="37%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:37.36%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="40%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:40.76%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="40%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:40.76%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SILICON ACQUISITION SUB, INC.</font></p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="40%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:40.76%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="40%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:40.76%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.4%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
  </td>
  <td width="30%" valign="top" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:30.46%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.9%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.4%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="37%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:37.36%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>
  </td>
 </tr>
 <tr>
  <td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.24%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.4%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="37%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:37.36%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">56</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>


<!-- SEQ.=1,FOLIO='56',FILE='C:\jms\mbrandt\03-4673-1\task38304\4673-1-kb.htm',USER='mbrandta',CD='Oct 31 15:25 2003' -->
</body>

</html>

</TEXT>
</DOCUMENT>
